US20120203466A1 - System and method for identifying disease-influencing genes - Google Patents
System and method for identifying disease-influencing genes Download PDFInfo
- Publication number
- US20120203466A1 US20120203466A1 US13/408,334 US201213408334A US2012203466A1 US 20120203466 A1 US20120203466 A1 US 20120203466A1 US 201213408334 A US201213408334 A US 201213408334A US 2012203466 A1 US2012203466 A1 US 2012203466A1
- Authority
- US
- United States
- Prior art keywords
- individuals
- individual
- queries
- groups
- responses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6887—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient mounted on external non-worn devices, e.g. non-medical devices
- A61B5/6896—Toys
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/40—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/04—Constructional details of apparatus
- A61B2560/0443—Modular apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/087—Measuring breath flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
- A61B5/743—Displaying an image simultaneously with additional graphical information, e.g. symbols, charts, function plots
Definitions
- This invention relates generally to the fields of genomics, bioinformatics, and drug development. More specifically, it relates to a database containing phenotypic and environmental data on groups of individuals for use in conjunction with gene sequences to identify disease-influencing genes and substances.
- Genes are comprised of DNA, which in turn consists of four nucleotides known as adenine(A), thymine(T), cytosine(C), and guanine(G).
- a particular series of nucleotides known as adenine(A), thymine(T), cytosine(C), and guanine(G).
- Each gene sequence codes for a protein.
- a defective or mutant gene sequence will not produce a working protein.
- the protein may not perform its purpose, the protein may carry out a different purpose than intended, too much protein may be made, too little protein may be made, or the protein may not be made at all. If the protein is essential to one or more functions of the body, disease will result.
- Mutant gene sequences are either inherited or acquired. An inherited gene sequence is received from an individual's parents, while an acquired gene sequence results from an event in the individuals lifetime which changes the original gene sequence.
- a classic example of an inherited mutant gene sequence is the sickle cell anemia gene.
- Sickle cell anemia is caused by the substitution of a single nucleotide (A to T) in the gene sequence of an individual. This single substitution results in the substitution of a single amino acid (glutamic acid to valine) in the resulting hemoglobin protein.
- the mutant hemoglobin protein produces crescent-shaped or sickled red blood cells in affected individuals, causing a decrease in the amount of oxygen that can be transported throughout the body. The lack of oxygen often results in kidney and heart failure, paralysis, and rheumatism, which are common symptoms of anemic individuals.
- malignant melanoma or skin cancer.
- Cancer results when normal cells in an individual's body either lose or gain certain functions, resulting in the unchecked growth of non-normal cells. These non-normal cells often form tumors and spread throughout the body, disrupting normal cell functions.
- a cancer such as malignant melanoma is caused when the original gene sequence in epidermal cells is changed or mutated by an environmental factor, such as UV radiation.
- Our cells contain repair mechanisms to fix such problems, but over time the gene sequences in epidermal cells acquire more and more mutations. Mutant proteins are then produced and cellular functions are disrupted. The individual then has skin cancer.
- Another factor that should be considered when discussing genetic diseases is whether they are monogenic or polygenic in nature.
- Sickle cell anemia and cystic fibrosis are examples of monogenic diseases, as they are caused by a single gene sequence.
- Most types of cancer, asthma, and diabetes are examples of polygenic diseases, as they are caused by a variety of genes.
- Polygenic diseases are also more likely to be influenced by an individual's environment. Not surprisingly, polygenic diseases are more difficult to diagnose and treat. Thus, the use of gene sequences in developing new drugs is dependent the monogenic or polygenic nature of genetic diseases.
- Genomics companies can typically be classified into one of two groups.
- the first group concentrates on gene sequencing in order to find both drug targets and drug candidates, usually in the form of proteins expressed by the gene sequences.
- Gene sequencing can either be in the form of random discovery, whereby genes are sequenced without regard to their functions, or in the form of targeted discovery, whereby a certain region of the genome which is tentatively associated with a disease is sequenced.
- random discovery gene sequencing potentially useful gene sequences are identified and assayed to determine if they can be used in drug development.
- One problem with random discovery gene sequencing is that the majority of the human genome contains introns, or gene sequences which do not code for proteins.
- sequence complementary DNA (cDNA) instead.
- cDNA is produced from messenger RNA (mRNA).
- mRNA messenger RNA
- mRNA messenger RNA
- mRNA messenger RNA
- mRNA messenger RNA
- mRNA messenger RNA
- mRNA messenger RNA
- mRNA is transcribed from DNA and processed by certain enzymes which remove the introns. cDNA sequences
- Targeted discovery gene sequencing is typically used with positional cloning, comparative gene expression, and functional cloning techniques, which are described in the next group.
- the second group of genomics companies takes a more epidemiological approach by first researching families or groups of individuals having a similar disease, and then isolating the relevant genes.
- this method also known as positional cloning, blood samples are taken from the individuals and analyzed.
- the blood samples contain DNA, which is studied to identify certain regions of the genome which appear to be associated with the disease. Linking a region of the genome with a disease is known as linkage analysis or genetic linkage mapping. Once a region of the genome has been identified, it is sequenced via targeted discovery gene sequencing.
- the second group of genomics companies also uses comparative gene expression to discover disease gene sequences.
- mRNA from both healthy and diseased tissue is isolated.
- the mRNA is then used to produce cDNA, which is sequenced using targeted discovery gene Sequencing.
- the gene sequences from both the healthy and diseased tissue are then compared.
- the identification of genes associated with disease can be made by studying the level of expression of genes in both the healthy and diseased tissue.
- Another similar technique is functional cloning. Mutant or non-functional proteins in metabolic pathways are studied and identified. The proteins are sequenced using targeted discovery gene sequencing and these sequences are used to figure out the corresponding DNA gene sequences. Once the disease gene sequences have been identified, they can be used in drug development.
- Incyte Pharmaceuticals (Palo Alto, Calif.). Incyte uses random discovery gene sequencing to produce its LifeSeqTM and LifeSeq FLTM databases. These databases contain the sequences of hundreds of human genes. These databases are licensed to drug development companies who use the sequences to produce new drugs. Databases covering animals (ZooSeqTM), plants (PhytoSeqTM), and bacteria and fungi (PathoSeqTM) are also available. Incyte has also developed bioinformatics software, which provides sequence analysis and data management for their databases. In addition, Incyte offers cDNA libraries of the gene sequences in their databases, which can be directly used in drug development.
- HGS Human Genome Sciences (Rockville, Md.) also concentrates on random discovery gene sequencing, and has sequenced an estimated 90% of the 100,000 genes in the human body. In addition to collaborating with drug development companies who use their gene sequences, HGS also has its own drug discovery and development division. A number of therapeutic proteins which appear effective in animal models are under study.
- Hyseq, Inc. (Sunnyvale, Calif.) has its HvX Platform which is capable of processing and sequencing millions of blood and DNA samples.
- the HyX Platform includes DNA arrays of samples and probes, software-driven modules, industrial robots for screening DNA probes against DNA samples, and bioinformatic software to analyze the genetic information.
- HyX believes it can carry out a variety of techniques, such as gene identification, gene expression level determination, gene interaction studies (for polygenic diseases), and genetic mapping.
- Affymetrix, Inc. (Santa Clara, Calif.) has a GeneChip system consisting of disposable DNA probe arrays containing gene sequences on a chip, instruments to process the probe arrays, and software to analyze and manage the genetic information in the probe.
- the GeneChip system thus allows pharmaceutical and biotechnology companies to collect gene sequences and apply them to drug development.
- the pharmaceutical industry has a number of genomics companies who first identify the genes which are likely to cause disease. After the genes are identified, they are sequenced and the gene sequences are used in drug development. Likewise, proteins implicated in disease can be identified and sequenced. The sequences can be used to discover the gene sequences, which are then used in drug development.
- Myriad genetics, Inc. targets families with a history of genetic disease and collects their genetic material in order to identify hereditary disease-causing genes, Myriad is able to identify these genes by using positional cloning and protein interaction studies in combination with targeted discovery gene sequencing. Using these techniques, Myriad has been able to locate and identify eight disease-related gene sequences, including BRCA1 and BRCA2. These gene sequences are used by Myriad's pharmaceutical partners to develop new therapeutics.
- Sequana Another genomics company which uses disease inheritance patterns together with gene sequencing is Sequana (La Jolla, Calif.). Sequana uses DNA collection of individuals with inherited diseases, genotyping and linkage analysis, physical mapping, and gene sequencing to find disease gene sequences. Sequana also has a proprietary bioinformatics system which includes data mining tools to automatically sort and organize much of its data. Like Myriad, Sequana has a number of alliances with drug development companies which license Sequana's gene sequences.
- Millennium Pharmaceuticals, Inc. employs a broader range of technologies than Myriad and Sequana.
- Millennium uses a number of other non-genetic techniques. cDNA libraries are prepared from mouse tissues and expressed using rapid expression of differential gene expression (RARE) technology. Different patterns of cDNA gene expression allow researchers to identify possible disease targets.
- RARE differential gene expression
- Millennium also uses functional cloning techniques in order to identify the gene sequences of interesting proteins. Once a potentially useful gene sequence has been identified, biological assays and bioinformatics are used as additional analyses.
- Genome Therapeutics Corporation uses a combination of positional cloning techniques and targeted discovery gene sequencing, as well as random discovery gene sequencing to isolate and identify disease gene sequences.
- Genome Therapeutics also has pathogen programs, which sequence pathogen genomes. As many non-genetic human diseases result from infection by pathogens, Genome Therapeutics hopes to eliminate pathogens by developing drugs and vaccines using the pathogens' genomes.
- Gene Logic, Inc. (Columbia, Md.) has an accelerated drug discovery system which emphasizes its restriction enzyme analysis of differentially expressed sequences (READS) technology.
- READS is similar in nature to comparative gene expression technology. In READS, normal and diseased tissues are compared in order to identify gene expression differences between the two. Genes which appear to be important in the diseased tissue are then analyzed. Restriction enzymes, which cut gene sequences at specific sites, are used to produce gene fragments. The gene fragments from the normal and diseased tissues will differ and can be compared.
- Gene Logic also has a Flow-thru Chip and genomic databases, which it licenses to drug development companies.
- Progenitor (Columbus, Ohio) focuses on developmental biology. Growing cells and tissues are analyzed for their level of expression of certain genes. Study of growing cells and tissues may help discover treatments for diseases characterized by abnormal cell growth, such as cancer and osteoporosis. Progenitor also uses bioinformatics, gene mapping, and gene sequencing to isolate, identify, and sequence relevant gene sequences.
- OncorMed, Inc. (Gaithersburg, Md.) has focused on the development of medical services using genetic information. Oncormed offers a number of tests for hereditary diseases such as breast and colon cancers and malignant melanoma.
- the medical services include measurements of replication error rates in tumors, molecular profiling of tumor suppresser genes, and gene sequencing.
- OncorMed has a genomics repository containing known cancer gene sequences.
- U.S. Pat. No. 5,642,936 issued to Evans and assigned to OncorMed describes a method for identifying human hereditary disease patterns. According to the method, data is collected on individuals having a history of disease within their families. Factors related to each disease are given weights, and the weights for each individual are summed. If the sum is above a certain predetermined threshold value, the individual is deemed to have a hereditary risk for the disease. Records from a number of individuals having a hereditary risk for a disease are collected to form a database.
- hereditary disease Gene sequencing and positional cloning represent the two approaches generally taken. However, very little emphasis is put on the environmental aspect of hereditary disease.
- An individual's environment is defined as his or her physical surroundings, geographical location, diet, lifestyle, etc. For many diseases which are genetic in origin, such as most cancers, an individual's environment plays a large role in determining whether or not the individual eventually develops the disease. Some individuals who have disease gene sequences develop diseases, while others who carry the exact same disease gone sequences do not.
- One purpose of collecting environmental data about individuals whose gene sequences are studied is to effectively rule out any non-genetic causes of disease. Another purpose is to discover if any individuals who are carrying disease gene sequences but who do not develop the disease have other compensatory gene sequences or factors which enable them to live disease-free.
- the second group of genomics companies do take into account a small amount of environmental data when they select individuals whose DNA they use for positional cloning analyses.
- the environmental data is usually in the form of a questionnaire or survey.
- the data is typically limited in scope to lifestyle questions, and is used only to help narrow the search for the specific disease gene in question.
- genomics companies are reluctant to share their data on individuals' with others, even those genomics companies which are studying the same gene sequences.
- each genomics company must gather its own data on individuals having a certain disease.
- Sequana sent its own researcher to the island of Tristan de Cunha to study hereditary asthma, while Myriad is located in Salt Lake City to take advantage of the detailed family trees of the Mormons.
- gathering environmental data on individuals is often an expensive, time-consuming, but necessary step. Genomics companies could potentially spend more of their time and money on actual disease gene isolation if they were able to obtain necessary environmental data from another source.
- genomics companies do gather environmental data on the individuals whose gene sequences are studied, the environmental data represents only a small time frame of an individual's life. Few genomics companies continually collect data over a long period of time, and as a result, are not able to definitively rule out certain environmental factors which may affect disease progression. In addition, such data collections are unlikely to provide leads for factors which may prohibit the formation of disease.
- the method includes the step of selecting individuals having a risk factor for a certain disease.
- Each of the individuals is provided with a remotely programmable apparatus having a user interface for communicating queries to the individuals and for receiving responses.
- Each apparatus also includes a communication device, such as a modem, for communicating with a server through a communication network.
- Queries relating to the individuals' environment are entered into the server and transmitted from the server to each individual's remote apparatus. After the individuals' have responded to the queries, the responses are sent back to the server and organized into a database. Data mining software is then used to distinguish the individuals into groups based on their environmental profiles. After a period of time, each group is then further divided into categories based on their disease progression. The genomes of all the individuals are then sequenced. Data mining techniques are used to find gene differences between the categories.
- the individuals are first separated into groups according to their disease progressions. Data mining techniques are then used to further distinguish each group into categories based on the individuals' environmental profiles. The genomes of all the individuals are then sequenced, and data mining techniques are used to find gene differences between the categories.
- a third embodiment of the invention provides a method for identifying disease-influencing substances.
- the method includes the step of selecting individuals having a risk factor for a certain disease.
- Each of the individuals is provided with a remotely programmable apparatus having a user interface for communicating queries to the individuals and for receiving responses.
- Each apparatus also includes a communication device, such as a modem, for communicating with a server through a communication network.
- Queries relating to the individuals' environment are entered into the server and transmitted from the server to each individual's remote apparatus. After the individuals' have responded to the queries, the responses are sent back to the server and organized into a database. The genomes of all the individuals are then sequenced. The individuals are placed into groups based on their gene sequences. Each group is then separated into categories based on the individuals' disease progression. Data mining techniques are then used to find a disease-influencing substance between the categories of individuals by using the individuals environmental profiles.
- the disease-influencing gene or substance isolated using these methods is preferably used to develop drug candidates or drug targets Additionally, the isolation of the disease-influencing gene is preferably used to identify a corresponding disease-influencing protein, which can also be used to develop drug candidates or drug targets.
- the present invention also provides a database and data processing system for storing and analyzing environmental information about individuals.
- the database and data processing system comprise a server for storing queries and the individuals' responses to the queries.
- the system also includes at least one remotely programmable apparatuses having a user interface for communicating queries to the individuals' and for receiving the responses.
- Each apparatus also includes a communication device, such as a modem, for communicating with the server through a communication network.
- the system also includes genotyping means in communication with the server for determining the individuals' gene sequences and a data mining software program accessible to the server for analyzing the individuals' gene sequences and environmental profiles.
- the data mining program includes: means for analyzing the responses in order to group the individuals having a similar behavioral and environmental profile, a similar disease progression, and a similar genotype; means for analyzing the responses in order to group the individuals having a similar disease progression; means for analyzing the responses in order to group the individuals-having a similar genotype; and means for identifying a disease-influencing gene or substance.
- the database can be used with other genomics or bioinformatics databases and systems if the information is to be manipulated in different ways.
- FIG. 1 is a block diagram of a networked system according to a preferred embodiment of the invention.
- FIG. 2 is a block diagram illustrating the interaction of the components of the system of FIG. 1 .
- FIG. 3 is a perspective view of a remotely programmable apparatus of the system of FIG. 1 .
- FIG. 4 is a block diagram illustrating the components of the apparatus of FIG. 3 .
- FIG. 5 is a script entry screen according to the preferred embodiment of the invention.
- FIG. 6A is a listing of a sample script program according to the preferred embodiment of the invention.
- FIG. 6B is a continuation of the listing of FIG. 6A .
- FIG. 7 is a script assignment screen according to the preferred embodiment of the invention.
- FIG. 8 is a sample query appearing on a display of the apparatus of FIG. 3 .
- FIG. 9 is a sample prompt appearing on the display of the apparatus of FIG. 3 .
- FIG. 10 is a sample report displayed on a workstation of the system of FIG. 1 .
- FIG. 11 is a flow chart illustrating the steps included in a monitoring application executed by the server of FIG. 1 according to the preferred embodiment of the invention.
- FIG. 12 is a flow chart illustrating the steps included in the script program of FIGS. 6A-6B .
- FIG. 13 is a sample completed data table of the present invention.
- FIG. 14 is a sample completed data table of the present invention.
- FIG. 15 is a flow chart illustrating a first method for identifying a gene according to the present invention.
- FIG. 16 is a block diagram illustrating the method of FIG. 15 .
- FIG. 17 is a flow chart illustrating a second method for identifying a gene according to the present invention.
- FIG. 18 is a block diagram illustrating the method of FIG. 17 .
- FIG. 19 is a flow chart illustrating a third method according to the present invention.
- FIG. 20 is a block diagram illustrating the method of FIG. 19 .
- the invention presents a system and method for creating a database containing environmental information about an individual to be used in conjunction with the individual's gene sequences to find new drug targets and drug candidates.
- remote monitors are used to collect the environmental information. It is to be understood that environmental information includes all non-genetic information about an individual, such as disease progression, diet, lifestyle, and geographical location.
- a networked system includes a server 50 and a workstation 52 connected to server 50 through a communication network 58 .
- Server 50 is also connected to a patient profile database 54 which stores environmental information about the individuals.
- Server 50 is further connected to a genotyping system 56 which is capable of sequencing individuals' genomes.
- Patient profile database 54 and genotyping system 56 are connected to server 50 through communication network 58 .
- Server 50 and patient profile database 54 are preferably world wide web servers.
- Server 50 and database 64 may comprise single stand-alone computers or multiple computers distributed throughout a network.
- Workstation 52 is preferably a personal computer, remote terminal, or web TV unit. Workstation 52 functions as a remote interface for entering in server 50 messages and queries to be communicated to the individuals.
- Genotyping system 55 can be a laboratory capable of sequencing individuals' genomes, a gene sequencing chip such as the GeneChip by Affymetrix, or any other suitable genotyping system.
- Genotyping system 56 should be capable of transmitting information about the individuals' genomes to server 50 .
- Communication network 58 connects workstation 52 , patient profile database 54 , and genotyping system 56 to server 50 .
- Communication network 58 can be any suitable communication network, such as a telephone cable, the Internet, or cellular or wireless communication. Such communication networks are well known in the art.
- the system also includes remotely programmable apparatuses 60 for monitoring individuals.
- each remote apparatus 60 is used to monitor a respective one of the individuals.
- a multi-user apparatus may be used to monitor a plurality of individuals.
- Each remote apparatus is designed to interact with an individual in accordance with script programs received from server 50 .
- Each remote apparatus is in communication with server 50 through communication network 58 , which is preferably the Internet.
- each remote apparatus may be placed in communication with the server via telephone cable, cellular communication, wireless communication, etc.
- FIG. 1 For clarity of illustration, only two remote apparatuses are shown in FIG. 1 . It is to be understood that the system may include any number of remote apparatuses for monitoring any number of individuals.
- each individual to be monitored is also provided with a monitoring device 64 .
- Monitoring device 64 is designed to produce measurements of a physiological condition of the individual, record the measurements, and transmit the measurements to the individual's remote apparatus 60 through a standard connection cable 62 .
- suitable monitoring devices include blood glucose meters, respiratory flow meters, blood pressure cuffs, electronic weight scales, and pulse rate monitors. Such monitoring devices are well known in the art.
- the specific type of monitoring device provided to each individual is dependent upon the individual's disease. For example, diabetes patients are provided with blood glucose meters for measuring blood glucose concentrations, asthma patients are provided with respiratory flow meters for measuring peak flow rates, obesity patients are provided with weight scales, etc.
- FIG. 2 shows server 50 , workstation 52 , and remote apparatus 60 in greater detail.
- Server 50 includes a database 66 for storing script programs 68 .
- the script programs 68 are executed by each remote apparatus 60 to communicate queries and messages to an individual, receive responses 70 to the queries, collect monitoring device measurements 72 , and transmit responses 70 and measurements 72 to server 50 .
- Database 66 is designed to store the responses 70 and measurements 72 .
- Database 66 further includes a look-up table 74 .
- Table 74 contains a list of the individuals to be monitored, and for each individual, a unique individual identification code and a respective pointer to script program 68 assigned to the individual.
- Each remote apparatus 60 is designed to execute the assigned script program which it receives from server 50 .
- FIGS. 3-4 show the structure of remote apparatus 50 according to the preferred embodiment.
- remote apparatus 60 includes a housing 90 .
- Housing 90 is preferably sufficiently compact to enable the remote apparatus to be hand-held and carried by an individual.
- Remote apparatus 60 also includes a user interface for communicating queries to the individual and for receiving responses to the queries.
- the user interface includes a display 92 and four user input buttons 98 A, 98 B, 98 C, and 98 D.
- Display 92 displays queries and prompts to the individual, and is preferably a liquid crystal display (LCD).
- the user input buttons 98 A, 98 B, 98 C, and 98 D are for entering responses to the queries and prompts.
- the user input buttons are preferably momentary contact push buttons.
- the user interface of the preferred embodiment includes a display and input buttons, it will be apparent to one skilled in the art of electronic devices that any suitable user interface may be used in remote apparatus 60 .
- the user input buttons may be replaced by switches, keys, a touch sensitive display screen, or any other data input device.
- the display and input buttons may be replaced by a speech synthesis/speech recognition interface.
- Three monitoring device jacks 96 A, 96 B, and 96 C are located on a surface of housing 90 .
- Device jacks 96 A, 96 B, and 96 C are for connecting remote apparatus 60 to a number of monitoring devices, such as blood glucose meters, respiratory flow meters, or blood pressure cuffs, through standard connection cables (not shown).
- Remote apparatus 60 also includes a modem jack 94 for connecting remote apparatus 60 to a telephone jack through a standard connection cord (not shown).
- Remote apparatus 60 further includes a visual indicator, such as a light emitting diode (LED) 100 .
- LED 100 is for visually notifying the individual that he or she has unanswered queries stored in remote apparatus 60 .
- FIG. 4 is a schematic block diagram illustrating the components of remote apparatus 60 in greater detail.
- Remote apparatus 60 includes a microprocessor 102 and a memory 108 connected to microprocessor 102 .
- Memory 108 is preferably a non-volatile memory, such as a serial EEPROM.
- Memory 108 stores script programs received from the server, measurements received from monitoring device 64 , responses to queries, and the individual's unique identification code.
- Microprocessor 102 also includes built-in read only memory (ROM) which stores firmware for controlling the operation of remote apparatus 60 .
- the firmware includes a script interpreter used by microprocessor 102 to execute the script programs.
- the script interpreter interprets script commands which are executed by microprocessor 102 . Specific techniques for interpreting and executing script programs in this manner are well known in the art.
- Microprocessor 102 is preferably connected to memory 108 using a standard two-wire I 2 C interface. Microprocessor 102 is also connected to user input buttons 98 A, 98 B, 98 C, and 98 D, LED 100 , a clock 112 , and a display driver 110 . Clock 112 indicates the current date and time to microprocessor 102 . For clarity of illustration, clock 112 is shown as a separate component, but is preferably built into microprocessor 102 .
- Display driver 110 operates under the control of microprocessor 102 to display information on display 92 .
- Microprocessor 102 is preferably a PIC 16C65 processor which includes a universal asynchronous receiver transmitter (DART) 104 . DART 104 is for communicating with a modem 114 and a device interface 118 . A CMOS switch 116 under the control of microprocessor 102 alternately connects modem 114 and interface 118 to DART 116 .
- DART universal asynchronous receiver transmitter
- Modem 114 is connected to a telephone jack 119 through modem jack 94 .
- Modem 114 is for exchanging data with the server through the communication network.
- the data includes script programs which are received from the server as well as responses to queries, device measurements, script identification codes, and the individual's unique identification code which modem 114 transmits to server 50 .
- Modem 114 is preferably a complete 28.8 K modem commercially available from Cermetek, although any suitable modem may be used.
- Device interface 118 is connected to device jacks 96 A, 96 B, and 96 C.
- Device interface 118 is for interfacing with a number of monitoring devices, such as blood glucose meters, respiratory flow meters, blood pressure cuffs, weight scales, or pulse rate monitors, through device jacks 96 A, 96 B, and 96 C.
- Device interface 118 operates under the control of microprocessor 102 to collect measurements 72 from monitoring devices 64 and to output measurements 72 to microprocessor 102 for storage in memory 108 .
- interface 118 is a standard RS232 interface. For simplicity of illustration, only one device interface 118 is shown in FIG. 4 . However, in alternative embodiments, remote apparatus 60 may include multiple device interfaces to accommodate monitoring devices which have different connection standards.
- server 50 includes a monitoring application 76 .
- Monitoring application 76 is a controlling software application executed by server 50 to perform the various functions described below.
- Monitoring application 76 includes a script generator 78 , a script assignor 80 , and a report generator 82 .
- Script generator 78 is designed to generate script programs 68 from script information entered through workstation 52 .
- the script information is entered through a script entry screen 84 .
- script entry screen 84 is implemented as a web page on the server 50 .
- Workstation 52 includes a web browser for accessing the web page to enter the script information.
- FIG. 5 illustrates script entry screen 84 as it appears on workstation 52 .
- Script entry screen 84 includes a script name field 120 for specifying the name of script program to be generated.
- Screen 84 also includes entry fields 122 for entering a set of queries to be answered by an individual. Each entry field 122 has corresponding response choice fields 124 for entering response choices for the query.
- Screen 84 further includes check boxes 126 for selecting a desired monitoring device type from which to collect measurements, such as a blood glucose meter, respiratory flow meter, or blood pressure cuff.
- Screen 84 additionally includes a connection time field 128 for specifying a prescribed connection time at which each remote apparatus executing the script program is to establish a subsequent communication link to the server.
- the connection time is preferably selected to be the time at which communication rates are the lowest, such as 3:00 AM.
- Screen 84 also includes a CREATE SCRIPT button 130 for instructing the script generator to generate a script program from the information entered in screen 84 .
- Screen 84 further includes a CANCEL button 132 for canceling the information entered.
- each script program created by the script generator 82 conforms to the standard file format used on UNIX systems.
- each command is listed in the upper case and followed by a colon. Every line in the script program is terminated by a linefeed character ⁇ LF ⁇ , and only one command is placed on each line.
- the last character in the script program is a UNIX end of file character (EOF).
- EEF UNIX end of file character
- INPUT OXOX ⁇ LF ⁇ allows the user to press either button #1 or #3.
- WAIT ⁇ LF ⁇ Wait for any one button to be pressed, then continue executing the script program.
- COLLECT device ⁇ LF ⁇ Collect measurements from the monitoring device specified in the COLLECT command. The user is preferably prompted to connect the specified monitoring device to the apparatus and press a button to continue.
- NUMBER aaaa ⁇ LF ⁇ Assign a script identification code to the script program. The script identification code from the most recently executed NUMBER statement is subsequently transmitted to the server along with the query responses and device measurements. The script identification code identifies to the server which script program was most recently executed by the remote apparatus.
- DELAY t ⁇ LF ⁇ Wait until time t specified in the DELAY command, usually the prescribed connection time.
- Script generator 78 preferably stores a script program template which it uses to create each script program. To generate a script program, script generator 78 inserts into the template the script information entered in script entry screen 84 .
- FIGS. 6A-6B illustrate a sample script program created by the script generator from the script information shown in FIG. 5 .
- the script program includes display commands to display the queries and response choices entered in fields 122 and 124 , respectively.
- the script program also includes input commands to receive responses to the queries.
- the script program further includes a collect command to collect device measurements from the monitoring device specified in check boxes 126 .
- the script program also includes commands to establish a subsequent communication link to the server at the connection time specified in field 128 .
- the steps included in the sample Script program are also shown in the flow chart of FIGS. 12A-12B and will be discussed in the operation section below.
- script assignor 80 is for assigning the script programs 68 to the individuals.
- the script programs are assigned in accordance with script assignment information entered through workstation 52 .
- the script assignment information is entered through a script assignment screen 86 , which is preferably implemented as a web page on server 50 .
- FIG. 7 shows a sample script assignment screen 86 as it appears on the workstation.
- Screen 86 includes check boxes 134 for selecting the script program to be assigned and check boxes 136 for selecting the individuals to whom the script program is to be assigned.
- Screen 86 also includes an ASSIGN SCRIPT button 140 for entering the assignments. When button 140 is pressed, s the script assignor creates and stores for each individual selected in check boxes 136 a respective pointer to the script program selected in check boxes 134 . Each pointer is stored in the look-up table 74 of database 66 .
- Screen 86 further includes an ADD SCRIPT button 138 for accessing the script entry screen and a DELETE SCRIPT button 142 for a deleting script program.
- report generator 82 is designed to generate a report 88 from the responses 70 and device measurements 72 received in server 50 .
- Report 88 is displayed on workstation 52 .
- FIG. 10 shows a sample patient report 88 produced by report generator 82 for a selected individual.
- Report 88 includes a graph 146 of the device measurements received from the individual, as well as a listing of the query responses received from the individual. Specific techniques for writing a report generator program to display data in this manner are well known in the software art.
- FIG. 11 is a flow chart illustrating steps included in the monitoring application executed by server 50 .
- the server determines if new script information has been entered through script entry screen 84 . If new script information has not been entere, the server proceeds to step 206 . If new script information has been entered, the server proceeds to step 204 .
- the script information includes a set of queries, and for each of the queries, corresponding responses choices.
- the script information also includes a selected monitoring device type from which to collect measurements.
- the script information further includes a prescribed connection time for each remote apparatus to establish a subsequent communication link to the server.
- the script information is generally entered in the server by a healthcare provider, such as the individuals' physician or case manager. Of course, any person desiring to communicate with the individual may also be granted access to the server to create and assign script programs. Further, it is to be understood that the system may include any number of workstations for entering script generation and script assignment information into the server.
- step 204 script generator 78 generates a script program from the information entered in screen 84 .
- the script program is stored in database 66 .
- Steps 202 and 204 are preferably repeated to generate multiple script programs, e.g. a script program for diabetes patients, a script program for asthma patients, etc.
- Each script program corresponds to a respective one of the sets of queries entered through script entry screen 84 .
- the server proceeds to step 206 .
- step 206 the server determines if new script assignment information has been entered through script assignment screen 86 . If new script assignment information has not been entered, the server proceeds to step 210 . If new script assignment information has been entered, the server proceeds to step 208 .
- script programs are assigned to each individual by selecting a script program through check boxes 134 , selecting the individuals to whom selected the script program is to be assigned through check boxes 136 , and pressing the ASSIGN SCRIPT button 140 .
- button 140 is pressed, script assignor 86 creates for each individual selected in check boxes 136 a respective pointer to the script program selected in check boxes 134 .
- each pointer is stored in look-up table 74 of database 66 . Following step 208 , the server proceeds to step 210 .
- step 210 the server determines if any of the remote apparatuses are remotely connected to the server.
- Each individual to be monitored is preferably provided with his or her own remote apparatus which has the individual's unique identification code stored therein. Each individual is thus uniquely associated with a respective one of the remote apparatuses. If none of remote apparatuses are connected, the server proceeds to step 220 .
- the server receives from the apparatus the individual's unique identification code in step 212 .
- the server receives from the apparatus the query responses, device measurements, and script identification code recorded during execution of a previously assigned script program.
- the script identification code identifies to the server which script program was executed by the remote apparatus to record the query responses and device measurements.
- the responses, device measurements, and script identification code are stored in database 66 .
- step 216 the server uses the individual's unique identification code to retrieve from look-up table 74 the pointer to the script program assigned to the individual. The server then retrieves the assigned script program froth the database 66 . In step 218 , the server transmits the assigned script program to the individual's remote apparatus through the communication network 58 . Following step 218 , the server proceeds to step 220 .
- step 220 the server determines if a report request has been received from workstation 52 . If no report request has been received, the server returns to step 202 . If a report request has been received for a selected individual, the server retrieves from database 66 the query responses and measurements last received from the individual, step 222 . In step 224 , the server generates and displays the report 88 on workstation 52 .
- the report includes the query responses and device measurements last received from the individual.
- the server returns to step 202 .
- FIG. 12 illustrates the steps included in a sample script program executed by the remote apparatus.
- the remote apparatus is initially programmed with the individual's unique identification code and the script interpreter used by microprocessor 102 to execute script programs.
- the initial programming may be achieved during manufacture or during an initial connection to the server.
- the remote apparatus receives from the server the script program assigned to the individual associated with the apparatus.
- the script program is received by modem 114 through a first communication link to the server and stored in memory 108 .
- microprocessor 102 assigns a script identification code to the script program and stores the script identification code in memory 108 .
- the script identification code is subsequently transmitted to the server along with query responses and device measurements to identify to the server which script program was most recently executed by the remote apparatus.
- microprocessor 102 lights LED 100 to notify the individual that he or she has unanswered queries stored in the remote apparatus. LED 100 preferably remains lit until the queries are answered by the individual.
- microprocessor 102 erases from memory 108 the last set of query responses recorded,
- microprocessor 102 prompts the individual by displaying on display 92 “ANSWER QUERIES NOW? PRESS ANY BUTTON TO START”.
- microprocessor 102 waits until a reply to the prompt is received from the individual. When a reply is received, microprocessor 102 proceeds to step 312 .
- microprocessor 102 executes successive display and input commands to display the queries and response choices on display 92 and to receive responses to the queries.
- FIG. 8 illustrate a sample query and its corresponding response choices as they appear on display 92 .
- the response choices are preferably positioned on display 92 such that each response choice is located proximate a respective one of the user input buttons 98 A, 98 B, 98 C, and 98 D.
- each response choice is displayed immediately above a respective user input button. The individual presses the button corresponding to his or her response, and microprocessor 102 stores the response in memory 108 .
- microprocessor 102 executes commands to collect device measurements from a selected monitoring device specified in the script program.
- microprocessor 102 prompts the individual to connect the selected device to one of the device jacks 96 A, 96 B, or 96 C.
- a sample prompt is shown in FIG. 9 .
- microprocessor 102 waits until a reply to the prompt is received from the individual. When a reply is received, microprocessor 102 proceeds to step 318 .
- Microprocessor 102 also connects UART 104 to device interface 118 through CMOS switch 116 .
- microprocessor 102 collects device measurements from the selected device through device interface 118 . The device measurements are stored in memory 108 .
- microprocessor 102 prompts the individual to connect remote apparatus 60 to telephone jack 119 so that the apparatus may connect to the server at the prescribed connection time.
- microprocessor 102 waits until a reply to the prompt is received from the individual. When a reply is received, microprocessor 102 turns off LED 100 in step 324 .
- microprocessor 102 waits until it is time to connect to the server.
- Microprocessor 102 compares the connection time specified in the script program to the current time output by clock 112 . When it is time to connect, microprocessor 102 connects DART 104 to modem 114 through CMOS switch 116 .
- microprocessor 102 establishes a subsequent communication link between remote apparatus 60 and server 50 through modem 114 and communication network 58 . If the connection fails for any reason, microprocessor 102 repeats step 328 to get a successful connection.
- microprocessor 102 transmits the query responses, device measurements, script identification code, and the individual's unique identification code stored in memory 108 to the server.
- microprocessor 102 receives through modem 114 a newly assigned script program from the server. The new script program is stored in memory 108 for subsequent execution by microprocessor 102 . Following step 332 , the script program ends.
- the data mining program includes a data table 150 , as shown in FIG. 13 .
- Data table 150 is stored on the server and has an individual identification number field 151 , name fields 152 , value fields 154 corresponding to the name fields, and explanation fields 156 corresponding to the name fields and value fields.
- the data type is entered into name fields 152 , the possible numerical values corresponding to the data type are entered into value fields 154 , and brief explanations of the data types and corresponding values are entered into explanation fields 156 .
- the individuals' device measurements and responses to the queries are entered into data table 150 in the form of numerical values in value fields 154 .
- the individual's identification number is entered into individual identification number field 151 .
- An example of data table 150 in which the individuals' information has been entered is shown in FIG. 14 . Once data table 150 contains all the necessary information, the data mining program then compares the information.
- FIG. 15 is a flowchart illustrating a first method of the present invention carried out by the server using the data mining techniques described above.
- step 400 individuals having a risk factor for a disease are selected.
- step 402 these individuals are queried about their behavior and environment using the script programs and remote apparatuses previously described.
- the responses to the queries and any device measurements are received and stored by the server. Collection of the responses and device measurements can occur over any period of time, thus allowing for more accurate data.
- a database comprising the individuals' behavioral and environmental profiles is created in step 404 .
- data mining techniques are used to group individuals having similar behavioral and environmental profiles.
- the server determines if it is necessary to further group the individuals in order to produce smaller groups. Steps 406 and 408 can be repeated as often as necessary.
- each group of individuals is categorized using data mining techniques.
- the individuals are categorized according to their disease progressions. For example, a group of individuals can be categorized into those that have a severe disease phenotype, those that have a moderate disease phenotype, and those that have a mild disease phenotype:
- the server determines if it is necessary to further categorize the individuals. Steps 410 and 412 can be repeated as often as necessary.
- step 414 the genomes of all the individuals are sequenced by genotyping system 56 .
- the genotypes of all the individuals are transmitted to server 50 .
- step 416 data mining techniques are used to compare the genotypes of the individuals between the categories. For example, if those individuals who have a severe disease phenotype and are overweight have a certain gene sequence, while those individuals who have a mild disease phenotype and are overweight do not, it Is likely the gene sequence is responsible for the severe disease phenotype. If a gene sequence is found, it is further identified in step 418 . Methods of isolating and identifying gene sequences are well known in the field.
- FIG. 16 is a block diagram illustrating an example of the first method of the present invention as described in FIG. 15 .
- First individuals having a risk factor for a certain disease such as is non-insulin dependent diabetes mellitus (NIDDM)
- NIDDM non-insulin dependent diabetes mellitus
- Behavioral and environmental information from each individual is collected using the script programs and remote apparatuses.
- the individuals are then grouped into overweight individuals 424 and non-overweight individuals 426 .
- the individuals are then categorized into overweight individuals having severe NIDDM 428 , overweight individuals having mild NIDDM 430 , non-overweight individuals having mild NIDDM 432 , and non-overweight individuals having severe NIDDM 434 .
- the individuals' genotype information is then taken, as indicated at block 436 , to determine the individuals' gene sequences. For example, overweight individuals with severe NIDDM have gene sequence A, overweight individuals with mild NIDDM have gene sequence B, non-overweight individuals with mild NIDDM have gene sequence B, and non-overweight individuals with severe NIDDM have gene sequence A. Data mining techniques are then used to analyze the information and come to a conclusion. In this example, data mining would conclude that the severe NIDDM phenotype is likely related to gene sequence A, not the individual's weight.
- FIG. 17 shows a flowchart illustrating a second method of the present invention carried out by the server using the data mining techniques described above.
- step 500 individuals having a risk factor for a disease are selected.
- step 502 these individuals are queried about their behavior and environment using the script programs and remote apparatuses previously described. The responses to the queries and any device measurements are received and stored by the server.
- a database comprising the individuals' behavioral and environmental profiles is created in step 504 .
- data mining techniques are used to group together individuals having similar disease progressions. For example, a group of individuals can be grouped into those that have a severe disease phenotype, those that have a moderate disease phenotype, and those that have a mild disease phenotype.
- the server determines if it is necessary to further group the individuals in order to produce smaller groups. Steps 506 and 508 can be repeated as often as necessary.
- each group of individuals created in steps 506 and 508 is categorized using data mining techniques according to the behavioral and environmental profiles of the individuals.
- the server determines if it is necessary to further group the individuals in order to produce smaller groups. Steps 510 and 512 can be repeated as often as necessary.
- step 514 the genomes of all the individuals are sequenced by genotyping system 56 .
- the genotypes of all the individuals are transmitted to the server.
- step 516 data mining techniques are used to compare the genotypes of the individuals between the categories. For example, if those individuals who have a severe disease phenotype and are overweight have a certain gene sequence, while those individuals who have a mild disease and are also overweight phenotype do riot, it is likely the gene sequence, not weight; is responsible for the severe disease phenotype. If a gene sequence is found, it is further identified in step 518 . Specific techniques of isolating and identifying gene sequences are well known in the field.
- FIG. 18 is a block diagram illustrating an example of the second method of the present invention as described in FIG. 17 .
- First individuals having a risk factor for a certain disease, such as NIDDM are chosen, as indicated at block 522 .
- Behavioral and environmental information from each individual is collected using the remote apparatuses and script programs.
- the individuals are then grouped into those exhibiting severe NIDDM 524 and those exhibiting mild NIDDM 525 .
- the individuals are then categorized into overweight individuals having severe NIDDM 528 , non--overweight individuals having severe NIDDM 530 , non-overweight individuals having mild NIDDM 532 , and overweight individuals having mild NIDDM 534 .
- the individuals' genotype information is then taken, as indicated at block 535 , to determine the individuals gene sequences. For example, individuals with severe NIDDM who are overweight have gene sequence A, individuals with severe NIDDM who are non-overweight have gene sequence A, individuals with mild NIDDM who are non-overweight have gene sequence B, and individuals with severe NIDDM who are overweight have gene sequence B.
- Data mining techniques are then used to analyze the information and come to a conclusion. In this example, data mining would conclude that the severe NIDDM phenotype is likely related to gene sequence A, not the individual's weight.
- FIG. 19 shows a flowchart illustrating a preferred method carried out by server 50 to identify a disease-identifying substance.
- step 600 individuals having a risk factor for a disease are selected.
- step 602 these individuals are queried about their behavior and environment using the script programs and remote apparatuses previously described. The responses to the queries and any device measurements are received and stored by the server.
- a database comprising the individuals' behavioral and environmental profiles is created in step 604 .
- the genomes of all the individuals are sequenced, and the genotypes of all the individuals are transmitted to the server.
- individuals having the sake or close genotypes are grouped together.
- data mining techniques are used to categorize together individuals having similar disease progressions.
- the server determines if it is necessary to further categorize the individuals in order to produce smaller groups. Steps 610 and 612 can be repeated as often as necessary.
- step 614 data mining techniques are used to find a disease-influencing substance between the categories of individuals by using the individuals behavioral and environmental profiles. For example, if those individuals who have a severe disease phenotype are overweight, while those individuals who have a mild disease phenotype are not, it is likely weight is responsible for the severe disease phenotype. If such a disease-influencing substance is found, it is identified in step 618 . If no disease-influencing substance is found, the process is preferably repeated.
- FIG. 20 is a block diagram illustrating an example of the method described in FIG. 19 .
- individuals having a risk factor for a certain disease such as NIDDM are chosen, as indicated at block 620 .
- Behavioral and environmental information from each individual is collected using the remote apparatuses and script programs.
- the individuals' genotype information is then taken, as indicated at block 622 , to determine the individuals' gene sequences.
- the individuals are then grouped according to their gene sequences. For example, one group may have gene sequence A, as indicated at block 624 , while another group may have gene sequence B, as indicated at block 626 .
- the individuals are then categorized into individuals with gene sequence A having severe NIDDM 628 , individuals with gene sequence A having mild NIDDM 630 , individuals with gene sequence B having mild NIDDM 632 , and individuals with gene sequence B having severe NIDDM 634 .
- Data mining techniques are further used to analyze the categories of individuals and their behavioral and environmental profiles. For example, overweight individuals 638 with severe NIDDM have gene sequence A, non-overweight individuals 640 with mild NIDDM have gene sequence A, overweight individuals 642 with mild NIDDM have gene sequence B, and non-overweight individuals 644 with severe NIDDM have gene sequence B. Data mining techniques are then used to analyze the information and come to a conclusion. In this example, data mining would conclude that the severe NIDDM phenotype is likely related to gene sequence A, not the individual's weight.
- the invention is not limited to the specific applications described.
- the system and method of the invention have many other applications.
- pharmaceutical manufacturers may apply the system in clinical trials to analyze new drug data.
Abstract
A system and method for using individuals' behavioral and environmental information in conjunction with their gene sequences to find drug candidates and drug targets. Individuals designated as having a high risk for developing a particular disease are each given a remotely programmable apparatus. Queries related to the individuals' behavior and environment are sent from a server to the remotely programmable apparatuses. The individuals' responses to the queries and any physiological information are sent back to the server. The process of collecting individuals' information can take place over a period of time to ensure accurate data and to allow researchers to observe progression of the disease. A data mining program on the server analyzes the individuals' behavioral and environmental information, as well as their gene sequences.
Description
- This is a continuation of U.S. Ser. No. 13/303,622, filed Nov. 23, 2011, which is a continuation of U.S. Ser. No. 09/496,893, filed Feb. 2, 2000, which are each herein incorporated by reference.
- This application is related to copending patent application Ser. No. 08/946,341 filed Oct. 7, 1997 which is herein incorporated by reference.
- This invention relates generally to the fields of genomics, bioinformatics, and drug development. More specifically, it relates to a database containing phenotypic and environmental data on groups of individuals for use in conjunction with gene sequences to identify disease-influencing genes and substances.
- The physical makeup of an individual is determined by his or her genes. Genes are comprised of DNA, which in turn consists of four nucleotides known as adenine(A), thymine(T), cytosine(C), and guanine(G). A particular series of nucleotides
- is known as a gene sequence. Each gene sequence codes for a protein. A defective or mutant gene sequence will not produce a working protein. The protein may not perform its purpose, the protein may carry out a different purpose than intended, too much protein may be made, too little protein may be made, or the protein may not be made at all. If the protein is essential to one or more functions of the body, disease will result.
- Mutant gene sequences are either inherited or acquired. An inherited gene sequence is received from an individual's parents, while an acquired gene sequence results from an event in the individuals lifetime which changes the original gene sequence.
- A classic example of an inherited mutant gene sequence is the sickle cell anemia gene. Sickle cell anemia is caused by the substitution of a single nucleotide (A to T) in the gene sequence of an individual. This single substitution results in the substitution of a single amino acid (glutamic acid to valine) in the resulting hemoglobin protein. The mutant hemoglobin protein produces crescent-shaped or sickled red blood cells in affected individuals, causing a decrease in the amount of oxygen that can be transported throughout the body. The lack of oxygen often results in kidney and heart failure, paralysis, and rheumatism, which are common symptoms of anemic individuals.
- An example of an acquired mutant gene sequence is malignant melanoma, or skin cancer. Cancer results when normal cells in an individual's body either lose or gain certain functions, resulting in the unchecked growth of non-normal cells. These non-normal cells often form tumors and spread throughout the body, disrupting normal cell functions. A cancer such as malignant melanoma is caused when the original gene sequence in epidermal cells is changed or mutated by an environmental factor, such as UV radiation. Our cells contain repair mechanisms to fix such problems, but over time the gene sequences in epidermal cells acquire more and more mutations. Mutant proteins are then produced and cellular functions are disrupted. The individual then has skin cancer.
- Although an individual's environment generally precipitates the development of cancer, many individuals have been found to have a predisposition to cancer. These individuals have gene sequences which are more likely to become mutated over a shorter period of time. Examples of such gene sequences are the BRCA1 and BRCA2 genes. Women carrying these gene sequences have a higher probability of,developing breast and ovarian cancer than women who carry normal gene sequences. Thus, although the affected women's original gene sequences may not be mutated, they are more likely to become mutated due to their sequence or location on a chromosome.
- Another factor that should be considered when discussing genetic diseases is whether they are monogenic or polygenic in nature. Sickle cell anemia and cystic fibrosis are examples of monogenic diseases, as they are caused by a single gene sequence. Most types of cancer, asthma, and diabetes are examples of polygenic diseases, as they are caused by a variety of genes. Polygenic diseases are also more likely to be influenced by an individual's environment. Not surprisingly, polygenic diseases are more difficult to diagnose and treat. Thus, the use of gene sequences in developing new drugs is dependent the monogenic or polygenic nature of genetic diseases.
- Typically, individuals with diseases caused by inherited or acquired gene sequences have only their symptoms treated. Diabetes patients receive insulin shots to regulate their blood glucose levels, asthma patients use inhalers to allow normal respiratory functions, and cancer patients undergo chemotherapy and radiation therapy to remove cancerous tumors. Although these treatments are often able to alleviate or eliminate the symptoms, they are unable to remove the genetic bases of the diseases.
- The genetic bases of many diseases were discovered in the 1940's by scientists such as Beadle and Tatum, who discovered that each gene codes for a protein. Researchers then rationalized that study of the relevant gene sequences could lead to effective drug treatments for genetic diseases. The technology was inadequate, however, until the 1970-80's, when Boyer and Cohen cloned DNA; Maxam, Gilbert, and Sanger figured out how to sequence DNA; and Mullis developed the polymerase chain reaction (PCR) technique to quickly amplify DNA sequences. Using genetics to find drug candidates soon became a practical option.
- Before these techniques became available, the pharmaceutical industry's main method of finding new drugs was trial and error. Compounds that were found to mimic the body's natural compounds were tested in vitro, in animal models, and in clinical trials to see if they had a desirable effect in treating disease. This method is still used and has resulted in many well-known drugs, but it is expensive and time-consuming.
- With the advent of improved genetic techniques, however, the pharmaceutical industry has begun concentrating on genetics as the most effective route to new drug discovery. Genomics companies can typically be classified into one of two groups.
- The first group concentrates on gene sequencing in order to find both drug targets and drug candidates, usually in the form of proteins expressed by the gene sequences. Gene sequencing can either be in the form of random discovery, whereby genes are sequenced without regard to their functions, or in the form of targeted discovery, whereby a certain region of the genome which is tentatively associated with a disease is sequenced. In random discovery gene sequencing, potentially useful gene sequences are identified and assayed to determine if they can be used in drug development. One problem with random discovery gene sequencing is that the majority of the human genome contains introns, or gene sequences which do not code for proteins. One way to circumvent this problem is to sequence complementary DNA (cDNA) instead. cDNA is produced from messenger RNA (mRNA). mRNA, in turn, is transcribed from DNA and processed by certain enzymes which remove the introns. cDNA sequences thus code for un-interrupted proteins.
- Targeted discovery gene sequencing is typically used with positional cloning, comparative gene expression, and functional cloning techniques, which are described in the next group.
- The second group of genomics companies takes a more epidemiological approach by first researching families or groups of individuals having a similar disease, and then isolating the relevant genes. In this method, also known as positional cloning, blood samples are taken from the individuals and analyzed. The blood samples contain DNA, which is studied to identify certain regions of the genome which appear to be associated with the disease. Linking a region of the genome with a disease is known as linkage analysis or genetic linkage mapping. Once a region of the genome has been identified, it is sequenced via targeted discovery gene sequencing.
- The second group of genomics companies also uses comparative gene expression to discover disease gene sequences. In comparative gene expression, mRNA from both healthy and diseased tissue is isolated. The mRNA is then used to produce cDNA, which is sequenced using targeted discovery gene Sequencing. The gene sequences from both the healthy and diseased tissue are then compared. In addition, the identification of genes associated with disease can be made by studying the level of expression of genes in both the healthy and diseased tissue.
- Another similar technique is functional cloning. Mutant or non-functional proteins in metabolic pathways are studied and identified. The proteins are sequenced using targeted discovery gene sequencing and these sequences are used to figure out the corresponding DNA gene sequences. Once the disease gene sequences have been identified, they can be used in drug development.
- Genomics companies in the first group include Incyte Pharmaceuticals (Palo Alto, Calif.). Incyte uses random discovery gene sequencing to produce its LifeSeq™ and LifeSeq FL™ databases. These databases contain the sequences of hundreds of human genes. These databases are licensed to drug development companies who use the sequences to produce new drugs. Databases covering animals (ZooSeq™), plants (PhytoSeq™), and bacteria and fungi (PathoSeq™) are also available. Incyte has also developed bioinformatics software, which provides sequence analysis and data management for their databases. In addition, Incyte offers cDNA libraries of the gene sequences in their databases, which can be directly used in drug development.
- Human Genome Sciences (Rockville, Md.) also concentrates on random discovery gene sequencing, and has sequenced an estimated 90% of the 100,000 genes in the human body. In addition to collaborating with drug development companies who use their gene sequences, HGS also has its own drug discovery and development division. A number of therapeutic proteins which appear effective in animal models are under study.
- Hyseq, Inc. (Sunnyvale, Calif.) has its HvX Platform which is capable of processing and sequencing millions of blood and DNA samples. The HyX Platform includes DNA arrays of samples and probes, software-driven modules, industrial robots for screening DNA probes against DNA samples, and bioinformatic software to analyze the genetic information. Through the use of its HyX Platform, HyX believes it can carry out a variety of techniques, such as gene identification, gene expression level determination, gene interaction studies (for polygenic diseases), and genetic mapping.
- Affymetrix, Inc. (Santa Clara, Calif.) has a GeneChip system consisting of disposable DNA probe arrays containing gene sequences on a chip, instruments to process the probe arrays, and software to analyze and manage the genetic information in the probe. The GeneChip system thus allows pharmaceutical and biotechnology companies to collect gene sequences and apply them to drug development.
- On the other hand, the pharmaceutical industry has a number of genomics companies who first identify the genes which are likely to cause disease. After the genes are identified, they are sequenced and the gene sequences are used in drug development. Likewise, proteins implicated in disease can be identified and sequenced. The sequences can be used to discover the gene sequences, which are then used in drug development.
- Myriad genetics, Inc. (Salt Lake City, Utah) targets families with a history of genetic disease and collects their genetic material in order to identify hereditary disease-causing genes, Myriad is able to identify these genes by using positional cloning and protein interaction studies in combination with targeted discovery gene sequencing. Using these techniques, Myriad has been able to locate and identify eight disease-related gene sequences, including BRCA1 and BRCA2. These gene sequences are used by Myriad's pharmaceutical partners to develop new therapeutics.
- Another genomics company which uses disease inheritance patterns together with gene sequencing is Sequana (La Jolla, Calif.). Sequana uses DNA collection of individuals with inherited diseases, genotyping and linkage analysis, physical mapping, and gene sequencing to find disease gene sequences. Sequana also has a proprietary bioinformatics system which includes data mining tools to automatically sort and organize much of its data. Like Myriad, Sequana has a number of alliances with drug development companies which license Sequana's gene sequences.
- Millennium Pharmaceuticals, Inc. (Cambridge, Mass.) employs a broader range of technologies than Myriad and Sequana. In addition to positional cloning and targeted discovery gene sequencing, Millennium uses a number of other non-genetic techniques. cDNA libraries are prepared from mouse tissues and expressed using rapid expression of differential gene expression (RARE) technology. Different patterns of cDNA gene expression allow researchers to identify possible disease targets. Millennium also uses functional cloning techniques in order to identify the gene sequences of interesting proteins. Once a potentially useful gene sequence has been identified, biological assays and bioinformatics are used as additional analyses.
- Genome Therapeutics Corporation (Waltham, Mass.) uses a combination of positional cloning techniques and targeted discovery gene sequencing, as well as random discovery gene sequencing to isolate and identify disease gene sequences. In addition, Genome Therapeutics also has pathogen programs, which sequence pathogen genomes. As many non-genetic human diseases result from infection by pathogens, Genome Therapeutics hopes to eliminate pathogens by developing drugs and vaccines using the pathogens' genomes.
- Gene Logic, Inc. (Columbia, Md.) has an accelerated drug discovery system which emphasizes its restriction enzyme analysis of differentially expressed sequences (READS) technology. READS is similar in nature to comparative gene expression technology. In READS, normal and diseased tissues are compared in order to identify gene expression differences between the two. Genes which appear to be important in the diseased tissue are then analyzed. Restriction enzymes, which cut gene sequences at specific sites, are used to produce gene fragments. The gene fragments from the normal and diseased tissues will differ and can be compared. Gene Logic also has a Flow-thru Chip and genomic databases, which it licenses to drug development companies.
- Progenitor (Columbus, Ohio) focuses on developmental biology. Growing cells and tissues are analyzed for their level of expression of certain genes. Study of growing cells and tissues may help discover treatments for diseases characterized by abnormal cell growth, such as cancer and osteoporosis. Progenitor also uses bioinformatics, gene mapping, and gene sequencing to isolate, identify, and sequence relevant gene sequences.
- OncorMed, Inc. (Gaithersburg, Md.) has focused on the development of medical services using genetic information. Oncormed offers a number of tests for hereditary diseases such as breast and colon cancers and malignant melanoma. The medical services include measurements of replication error rates in tumors, molecular profiling of tumor suppresser genes, and gene sequencing. In addition, OncorMed has a genomics repository containing known cancer gene sequences.
- U.S. Pat. No. 5,642,936 issued to Evans and assigned to OncorMed describes a method for identifying human hereditary disease patterns. According to the method, data is collected on individuals having a history of disease within their families. Factors related to each disease are given weights, and the weights for each individual are summed. If the sum is above a certain predetermined threshold value, the individual is deemed to have a hereditary risk for the disease. Records from a number of individuals having a hereditary risk for a disease are collected to form a database.
- The methods used by the above companies all focus on the genetic aspect of hereditary disease. Gene sequencing and positional cloning represent the two approaches generally taken. However, very little emphasis is put on the environmental aspect of hereditary disease. An individual's environment is defined as his or her physical surroundings, geographical location, diet, lifestyle, etc. For many diseases which are genetic in origin, such as most cancers, an individual's environment plays a large role in determining whether or not the individual eventually develops the disease. Some individuals who have disease gene sequences develop diseases, while others who carry the exact same disease gone sequences do not. One purpose of collecting environmental data about individuals whose gene sequences are studied is to effectively rule out any non-genetic causes of disease. Another purpose is to discover if any individuals who are carrying disease gene sequences but who do not develop the disease have other compensatory gene sequences or factors which enable them to live disease-free.
- To a certain extent, the second group of genomics companies do take into account a small amount of environmental data when they select individuals whose DNA they use for positional cloning analyses. The environmental data is usually in the form of a questionnaire or survey. However, the data is typically limited in scope to lifestyle questions, and is used only to help narrow the search for the specific disease gene in question.
- In addition, most genomics companies are reluctant to share their data on individuals' with others, even those genomics companies which are studying the same gene sequences. As a result, each genomics company must gather its own data on individuals having a certain disease. For example, Sequana sent its own researcher to the island of Tristan de Cunha to study hereditary asthma, while Myriad is located in Salt Lake City to take advantage of the detailed family trees of the Mormons. For genomics companies searching for gene sequences, gathering environmental data on individuals is often an expensive, time-consuming, but necessary step. Genomics companies could potentially spend more of their time and money on actual disease gene isolation if they were able to obtain necessary environmental data from another source.
- Another problem lies in the fact that when genomics companies do gather environmental data on the individuals whose gene sequences are studied, the environmental data represents only a small time frame of an individual's life. Few genomics companies continually collect data over a long period of time, and as a result, are not able to definitively rule out certain environmental factors which may affect disease progression. In addition, such data collections are unlikely to provide leads for factors which may prohibit the formation of disease.
- Accordingly, it is a primary object of the present invention to provide a system and method for creating a database of information about individuals' environments over a period of time. Another object of the present invention is to provide a database containing information about individuals' environments which can be used with existing genomics databases. A further object of the present invention is to provide a method of using environmental information about an individual in conjunction with the individual's genotype to find disease-influencing genes or substances. It is another object of the present invention to use the disease-influencing genes or substances to find drug candidates or drug targets.
- These objects and advantages are attained by a system and method for identifying a disease-influencing gene or protein. The method includes the step of selecting individuals having a risk factor for a certain disease. Each of the individuals is provided with a remotely programmable apparatus having a user interface for communicating queries to the individuals and for receiving responses. Each apparatus also includes a communication device, such as a modem, for communicating with a server through a communication network.
- Queries relating to the individuals' environment are entered into the server and transmitted from the server to each individual's remote apparatus. After the individuals' have responded to the queries, the responses are sent back to the server and organized into a database. Data mining software is then used to distinguish the individuals into groups based on their environmental profiles. After a period of time, each group is then further divided into categories based on their disease progression. The genomes of all the individuals are then sequenced. Data mining techniques are used to find gene differences between the categories.
- According to a second method of the invention, the individuals are first separated into groups according to their disease progressions. Data mining techniques are then used to further distinguish each group into categories based on the individuals' environmental profiles. The genomes of all the individuals are then sequenced, and data mining techniques are used to find gene differences between the categories.
- A third embodiment of the invention provides a method for identifying disease-influencing substances. The method includes the step of selecting individuals having a risk factor for a certain disease. Each of the individuals is provided with a remotely programmable apparatus having a user interface for communicating queries to the individuals and for receiving responses. Each apparatus also includes a communication device, such as a modem, for communicating with a server through a communication network.
- Queries relating to the individuals' environment are entered into the server and transmitted from the server to each individual's remote apparatus. After the individuals' have responded to the queries, the responses are sent back to the server and organized into a database. The genomes of all the individuals are then sequenced. The individuals are placed into groups based on their gene sequences. Each group is then separated into categories based on the individuals' disease progression. Data mining techniques are then used to find a disease-influencing substance between the categories of individuals by using the individuals environmental profiles.
- The disease-influencing gene or substance isolated using these methods is preferably used to develop drug candidates or drug targets Additionally, the isolation of the disease-influencing gene is preferably used to identify a corresponding disease-influencing protein, which can also be used to develop drug candidates or drug targets.
- The present invention also provides a database and data processing system for storing and analyzing environmental information about individuals. The database and data processing system comprise a server for storing queries and the individuals' responses to the queries. The system also includes at least one remotely programmable apparatuses having a user interface for communicating queries to the individuals' and for receiving the responses. Each apparatus also includes a communication device, such as a modem, for communicating with the server through a communication network.
- The system also includes genotyping means in communication with the server for determining the individuals' gene sequences and a data mining software program accessible to the server for analyzing the individuals' gene sequences and environmental profiles. In particular, the data mining program includes: means for analyzing the responses in order to group the individuals having a similar behavioral and environmental profile, a similar disease progression, and a similar genotype; means for analyzing the responses in order to group the individuals having a similar disease progression; means for analyzing the responses in order to group the individuals-having a similar genotype; and means for identifying a disease-influencing gene or substance. Alternatively, the database can be used with other genomics or bioinformatics databases and systems if the information is to be manipulated in different ways.
-
FIG. 1 is a block diagram of a networked system according to a preferred embodiment of the invention. -
FIG. 2 is a block diagram illustrating the interaction of the components of the system ofFIG. 1 . -
FIG. 3 is a perspective view of a remotely programmable apparatus of the system ofFIG. 1 . -
FIG. 4 is a block diagram illustrating the components of the apparatus ofFIG. 3 . -
FIG. 5 is a script entry screen according to the preferred embodiment of the invention. -
FIG. 6A is a listing of a sample script program according to the preferred embodiment of the invention. -
FIG. 6B is a continuation of the listing ofFIG. 6A . -
FIG. 7 is a script assignment screen according to the preferred embodiment of the invention. -
FIG. 8 is a sample query appearing on a display of the apparatus ofFIG. 3 . -
FIG. 9 is a sample prompt appearing on the display of the apparatus ofFIG. 3 . -
FIG. 10 is a sample report displayed on a workstation of the system ofFIG. 1 . -
FIG. 11 is a flow chart illustrating the steps included in a monitoring application executed by the server ofFIG. 1 according to the preferred embodiment of the invention. -
FIG. 12 is a flow chart illustrating the steps included in the script program ofFIGS. 6A-6B . -
FIG. 13 is a sample completed data table of the present invention. -
FIG. 14 is a sample completed data table of the present invention. -
FIG. 15 is a flow chart illustrating a first method for identifying a gene according to the present invention. -
FIG. 16 is a block diagram illustrating the method ofFIG. 15 . -
FIG. 17 is a flow chart illustrating a second method for identifying a gene according to the present invention. -
FIG. 18 is a block diagram illustrating the method ofFIG. 17 . -
FIG. 19 is a flow chart illustrating a third method according to the present invention. -
FIG. 20 is a block diagram illustrating the method ofFIG. 19 . - The invention presents a system and method for creating a database containing environmental information about an individual to be used in conjunction with the individual's gene sequences to find new drug targets and drug candidates. In a preferred embodiment of the invention, remote monitors are used to collect the environmental information. It is to be understood that environmental information includes all non-genetic information about an individual, such as disease progression, diet, lifestyle, and geographical location.
- A preferred embodiment of the invention is illustrated in
FIGS. 1-16 . Referring toFIG. 1 , a networked system includes aserver 50 and aworkstation 52 connected toserver 50 through acommunication network 58.Server 50 is also connected to apatient profile database 54 which stores environmental information about the individuals.Server 50 is further connected to agenotyping system 56 which is capable of sequencing individuals' genomes.Patient profile database 54 andgenotyping system 56 are connected toserver 50 throughcommunication network 58. -
Server 50 andpatient profile database 54 are preferably world wide web servers.Server 50 anddatabase 64 may comprise single stand-alone computers or multiple computers distributed throughout a network.Workstation 52 is preferably a personal computer, remote terminal, or web TV unit.Workstation 52 functions as a remote interface for entering inserver 50 messages and queries to be communicated to the individuals. - Genotyping system 55 can be a laboratory capable of sequencing individuals' genomes, a gene sequencing chip such as the GeneChip by Affymetrix, or any other suitable genotyping system.
Genotyping system 56 should be capable of transmitting information about the individuals' genomes toserver 50.Communication network 58 connectsworkstation 52,patient profile database 54, andgenotyping system 56 toserver 50.Communication network 58 can be any suitable communication network, such as a telephone cable, the Internet, or cellular or wireless communication. Such communication networks are well known in the art. - The system also includes remotely
programmable apparatuses 60 for monitoring individuals. Preferably, eachremote apparatus 60 is used to monitor a respective one of the individuals. Alternatively, a multi-user apparatus may be used to monitor a plurality of individuals. Each remote apparatus is designed to interact with an individual in accordance with script programs received fromserver 50. - Each remote apparatus is in communication with
server 50 throughcommunication network 58, which is preferably the Internet. Alternatively, each remote apparatus may be placed in communication with the server via telephone cable, cellular communication, wireless communication, etc. For clarity of illustration, only two remote apparatuses are shown inFIG. 1 . It is to be understood that the system may include any number of remote apparatuses for monitoring any number of individuals. - In the preferred embodiment, each individual to be monitored is also provided with a
monitoring device 64.Monitoring device 64 is designed to produce measurements of a physiological condition of the individual, record the measurements, and transmit the measurements to the individual'sremote apparatus 60 through astandard connection cable 62. Examples of suitable monitoring devices include blood glucose meters, respiratory flow meters, blood pressure cuffs, electronic weight scales, and pulse rate monitors. Such monitoring devices are well known in the art. - The specific type of monitoring device provided to each individual is dependent upon the individual's disease. For example, diabetes patients are provided with blood glucose meters for measuring blood glucose concentrations, asthma patients are provided with respiratory flow meters for measuring peak flow rates, obesity patients are provided with weight scales, etc.
-
FIG. 2 showsserver 50,workstation 52, andremote apparatus 60 in greater detail.Server 50 includes adatabase 66 for storingscript programs 68. The script programs 68 are executed by eachremote apparatus 60 to communicate queries and messages to an individual, receiveresponses 70 to the queries, collectmonitoring device measurements 72, and transmitresponses 70 andmeasurements 72 toserver 50.Database 66 is designed to store theresponses 70 andmeasurements 72.Database 66 further includes a look-up table 74. Table 74 contains a list of the individuals to be monitored, and for each individual, a unique individual identification code and a respective pointer to scriptprogram 68 assigned to the individual. Eachremote apparatus 60 is designed to execute the assigned script program which it receives fromserver 50. -
FIGS. 3-4 show the structure ofremote apparatus 50 according to the preferred embodiment. Referring toFIG. 3 ,remote apparatus 60 includes ahousing 90.Housing 90 is preferably sufficiently compact to enable the remote apparatus to be hand-held and carried by an individual.Remote apparatus 60 also includes a user interface for communicating queries to the individual and for receiving responses to the queries. - In the preferred embodiment, the user interface includes a
display 92 and fouruser input buttons Display 92 displays queries and prompts to the individual, and is preferably a liquid crystal display (LCD). Theuser input buttons remote apparatus 60. For example, the user input buttons may be replaced by switches, keys, a touch sensitive display screen, or any other data input device. Alternatively, the display and input buttons may be replaced by a speech synthesis/speech recognition interface. - Three monitoring device jacks 96A, 96B, and 96C are located on a surface of
housing 90. Device jacks 96A, 96B, and 96C are for connectingremote apparatus 60 to a number of monitoring devices, such as blood glucose meters, respiratory flow meters, or blood pressure cuffs, through standard connection cables (not shown).Remote apparatus 60 also includes amodem jack 94 for connectingremote apparatus 60 to a telephone jack through a standard connection cord (not shown).Remote apparatus 60 further includes a visual indicator, such as a light emitting diode (LED) 100.LED 100 is for visually notifying the individual that he or she has unanswered queries stored inremote apparatus 60. -
FIG. 4 is a schematic block diagram illustrating the components ofremote apparatus 60 in greater detail.Remote apparatus 60 includes amicroprocessor 102 and amemory 108 connected tomicroprocessor 102.Memory 108 is preferably a non-volatile memory, such as a serial EEPROM.Memory 108 stores script programs received from the server, measurements received from monitoringdevice 64, responses to queries, and the individual's unique identification code.Microprocessor 102 also includes built-in read only memory (ROM) which stores firmware for controlling the operation ofremote apparatus 60. The firmware includes a script interpreter used bymicroprocessor 102 to execute the script programs. The script interpreter interprets script commands which are executed bymicroprocessor 102. Specific techniques for interpreting and executing script programs in this manner are well known in the art. -
Microprocessor 102 is preferably connected tomemory 108 using a standard two-wire I2C interface.Microprocessor 102 is also connected touser input buttons LED 100, aclock 112, and adisplay driver 110.Clock 112 indicates the current date and time tomicroprocessor 102. For clarity of illustration,clock 112 is shown as a separate component, but is preferably built intomicroprocessor 102.Display driver 110 operates under the control ofmicroprocessor 102 to display information ondisplay 92.Microprocessor 102 is preferably a PIC 16C65 processor which includes a universal asynchronous receiver transmitter (DART) 104.DART 104 is for communicating with amodem 114 and adevice interface 118. ACMOS switch 116 under the control ofmicroprocessor 102 alternately connectsmodem 114 andinterface 118 toDART 116. -
Modem 114 is connected to atelephone jack 119 throughmodem jack 94.Modem 114 is for exchanging data with the server through the communication network. The data includes script programs which are received from the server as well as responses to queries, device measurements, script identification codes, and the individual's unique identification code whichmodem 114 transmits toserver 50.Modem 114 is preferably a complete 28.8 K modem commercially available from Cermetek, although any suitable modem may be used. -
Device interface 118 is connected todevice jacks Device interface 118 is for interfacing with a number of monitoring devices, such as blood glucose meters, respiratory flow meters, blood pressure cuffs, weight scales, or pulse rate monitors, throughdevice jacks Device interface 118 operates under the control ofmicroprocessor 102 to collectmeasurements 72 frommonitoring devices 64 and tooutput measurements 72 tomicroprocessor 102 for storage inmemory 108. In the preferred embodiment,interface 118 is a standard RS232 interface. For simplicity of illustration, only onedevice interface 118 is shown inFIG. 4 . However, in alternative embodiments,remote apparatus 60 may include multiple device interfaces to accommodate monitoring devices which have different connection standards. - Referring again to
FIG. 2 ,server 50 includes amonitoring application 76. Monitoringapplication 76 is a controlling software application executed byserver 50 to perform the various functions described below. Monitoringapplication 76 includes ascript generator 78, ascript assignor 80, and areport generator 82.Script generator 78 is designed to generatescript programs 68 from script information entered throughworkstation 52. The script information is entered through ascript entry screen 84. In the preferred embodiment,script entry screen 84 is implemented as a web page on theserver 50.Workstation 52 includes a web browser for accessing the web page to enter the script information. -
FIG. 5 illustratesscript entry screen 84 as it appears onworkstation 52.Script entry screen 84 includes ascript name field 120 for specifying the name of script program to be generated.Screen 84 also includes entry fields 122 for entering a set of queries to be answered by an individual. Eachentry field 122 has corresponding response choice fields 124 for entering response choices for the query.Screen 84 further includescheck boxes 126 for selecting a desired monitoring device type from which to collect measurements, such as a blood glucose meter, respiratory flow meter, or blood pressure cuff. -
Screen 84 additionally includes aconnection time field 128 for specifying a prescribed connection time at which each remote apparatus executing the script program is to establish a subsequent communication link to the server. The connection time is preferably selected to be the time at which communication rates are the lowest, such as 3:00 AM.Screen 84 also includes aCREATE SCRIPT button 130 for instructing the script generator to generate a script program from the information entered inscreen 84.Screen 84 further includes a CANCELbutton 132 for canceling the information entered. - In the preferred embodiment, each script program created by the
script generator 82 conforms to the standard file format used on UNIX systems. In the standard file format, each command is listed in the upper case and followed by a colon. Every line in the script program is terminated by a linefeed character {LF}, and only one command is placed on each line. The last character in the script program is a UNIX end of file character (EOF). TABLE 1 shows an exemplary listing of script commands used in the preferred embodiment of the invention. -
TABLE 1 SCRIPT COMMANDS Command Description CLS: {LF} Clear the display. ZAP: {LF} Erase from memory the last set of query responses recorded. LED: b{LF} Turn the LED on or off, where b is a binary digit of 0 or 1. An argument of 1 turns on the LED, and an argument of 0 turns off the LED. DISPLAY: {chars}{LF} Display the text following the DISPLAY command. INPUT: mmmm{LF} Record a button press. The m's represent a button mask pattern for each of the four input buttons. Each m contains an “X” for disallowed buttons or an “O” for allowed buttons. For example, INPUT: OXOX{LF} allows the user to press either button # 1 or #3.WAIT: {LF} Wait for any one button to be pressed, then continue executing the script program. COLLECT: device{LF} Collect measurements from the monitoring device specified in the COLLECT command. The user is preferably prompted to connect the specified monitoring device to the apparatus and press a button to continue. NUMBER: aaaa{LF} Assign a script identification code to the script program. The script identification code from the most recently executed NUMBER statement is subsequently transmitted to the server along with the query responses and device measurements. The script identification code identifies to the server which script program was most recently executed by the remote apparatus. DELAY: t {LF} Wait until time t specified in the DELAY command, usually the prescribed connection time. CONNECT: {LF} Perform a connection routine to establish a communication link to the server, transmit the patient identification code, query responses, device measurements, and script identification code to the server, and receive and store a new script program. When the server instructs the apparatus to disconnect, the script interpreter is restarted, allowing the new script program to execute. - The script commands illustrated in TABLE 1 are representative of the preferred embodiment and are not intended to limit the scope of the invention. After consideration of the ensuing description, it will be apparent to one skilled in the art many other suitable scripting languages and sets of script commands may be used to implement the system and method of the invention.
-
Script generator 78 preferably stores a script program template which it uses to create each script program. To generate a script program,script generator 78 inserts into the template the script information entered inscript entry screen 84. For example,FIGS. 6A-6B illustrate a sample script program created by the script generator from the script information shown inFIG. 5 . - The script program includes display commands to display the queries and response choices entered in
fields check boxes 126. The script program also includes commands to establish a subsequent communication link to the server at the connection time specified infield 128. The steps included in the sample Script program are also shown in the flow chart ofFIGS. 12A-12B and will be discussed in the operation section below. - Referring again to
FIG. 2 ,script assignor 80 is for assigning thescript programs 68 to the individuals. The script programs are assigned in accordance with script assignment information entered throughworkstation 52. The script assignment information is entered through ascript assignment screen 86, which is preferably implemented as a web page onserver 50. -
FIG. 7 shows a samplescript assignment screen 86 as it appears on the workstation.Screen 86 includescheck boxes 134 for selecting the script program to be assigned and checkboxes 136 for selecting the individuals to whom the script program is to be assigned.Screen 86 also includes an ASSIGNSCRIPT button 140 for entering the assignments. Whenbutton 140 is pressed, s the script assignor creates and stores for each individual selected in check boxes 136 a respective pointer to the script program selected incheck boxes 134. Each pointer is stored in the look-up table 74 ofdatabase 66.Screen 86 further includes anADD SCRIPT button 138 for accessing the script entry screen and aDELETE SCRIPT button 142 for a deleting script program. - Referring again to
FIG. 2 ,report generator 82 is designed to generate areport 88 from theresponses 70 anddevice measurements 72 received inserver 50.Report 88 is displayed onworkstation 52.FIG. 10 shows asample patient report 88 produced byreport generator 82 for a selected individual.Report 88 includes agraph 146 of the device measurements received from the individual, as well as a listing of the query responses received from the individual. Specific techniques for writing a report generator program to display data in this manner are well known in the software art. - The operation of the preferred embodiment is illustrated in
FIGS. 1-12 .FIG. 11 is a flow chart illustrating steps included in the monitoring application executed byserver 50. Instep 202, the server determines if new script information has been entered throughscript entry screen 84. If new script information has not been entere, the server proceeds to step 206. If new script information has been entered, the server proceeds to step 204. - As shown in
FIG. 5 , the script information includes a set of queries, and for each of the queries, corresponding responses choices. The script information also includes a selected monitoring device type from which to collect measurements. The script information further includes a prescribed connection time for each remote apparatus to establish a subsequent communication link to the server. The script information is generally entered in the server by a healthcare provider, such as the individuals' physician or case manager. Of course, any person desiring to communicate with the individual may also be granted access to the server to create and assign script programs. Further, it is to be understood that the system may include any number of workstations for entering script generation and script assignment information into the server. - In
step 204,script generator 78 generates a script program from the information entered inscreen 84. The script program is stored indatabase 66.Steps script entry screen 84. Followingstep 204, the server proceeds to step 206. - In
step 206, the server determines if new script assignment information has been entered throughscript assignment screen 86. If new script assignment information has not been entered, the server proceeds to step 210. If new script assignment information has been entered, the server proceeds to step 208. As shown inFIG. 7 , script programs are assigned to each individual by selecting a script program throughcheck boxes 134, selecting the individuals to whom selected the script program is to be assigned throughcheck boxes 136, and pressing the ASSIGNSCRIPT button 140. Whenbutton 140 is pressed,script assignor 86 creates for each individual selected in check boxes 136 a respective pointer to the script program selected incheck boxes 134. Instep 208, each pointer is stored in look-up table 74 ofdatabase 66. Followingstep 208, the server proceeds to step 210. - In
step 210, the server determines if any of the remote apparatuses are remotely connected to the server. Each individual to be monitored is preferably provided with his or her own remote apparatus which has the individual's unique identification code stored therein. Each individual is thus uniquely associated with a respective one of the remote apparatuses. If none of remote apparatuses are connected, the server proceeds to step 220. - If a remote apparatus is connected, the server receives from the apparatus the individual's unique identification code in
step 212. Instep 214, the server receives from the apparatus the query responses, device measurements, and script identification code recorded during execution of a previously assigned script program. The script identification code identifies to the server which script program was executed by the remote apparatus to record the query responses and device measurements. The responses, device measurements, and script identification code are stored indatabase 66. - In
step 216, the server uses the individual's unique identification code to retrieve from look-up table 74 the pointer to the script program assigned to the individual. The server then retrieves the assigned script program froth thedatabase 66. Instep 218, the server transmits the assigned script program to the individual's remote apparatus through thecommunication network 58. Followingstep 218, the server proceeds to step 220. - In
step 220, the server determines if a report request has been received fromworkstation 52. If no report request has been received, the server returns to step 202. If a report request has been received for a selected individual, the server retrieves fromdatabase 66 the query responses and measurements last received from the individual,step 222. Instep 224, the server generates and displays thereport 88 onworkstation 52. - As shown in
FIG. 10 , the report includes the query responses and device measurements last received from the individual. Followingstep 224, the server returns to step 202. -
FIG. 12 illustrates the steps included in a sample script program executed by the remote apparatus. Before the script program is received, the remote apparatus is initially programmed with the individual's unique identification code and the script interpreter used bymicroprocessor 102 to execute script programs. The initial programming may be achieved during manufacture or during an initial connection to the server. Following initial programming, the remote apparatus receives from the server the script program assigned to the individual associated with the apparatus. The script program is received bymodem 114 through a first communication link to the server and stored inmemory 108. - In
step 302,microprocessor 102 assigns a script identification code to the script program and stores the script identification code inmemory 108. The script identification code is subsequently transmitted to the server along with query responses and device measurements to identify to the server which script program was most recently executed by the remote apparatus. Instep 304,microprocessor 102 lights LED 100 to notify the individual that he or she has unanswered queries stored in the remote apparatus.LED 100 preferably remains lit until the queries are answered by the individual. Instep 306,microprocessor 102 erases frommemory 108 the last set of query responses recorded, - In
step 308,microprocessor 102 prompts the individual by displaying ondisplay 92 “ANSWER QUERIES NOW? PRESS ANY BUTTON TO START”. Instep 310,microprocessor 102 waits until a reply to the prompt is received from the individual. When a reply is received,microprocessor 102 proceeds to step 312. Instep 312,microprocessor 102 executes successive display and input commands to display the queries and response choices ondisplay 92 and to receive responses to the queries. -
FIG. 8 illustrate a sample query and its corresponding response choices as they appear ondisplay 92. The response choices are preferably positioned ondisplay 92 such that each response choice is located proximate a respective one of theuser input buttons microprocessor 102 stores the response inmemory 108. - In
steps 314 to 318,microprocessor 102 executes commands to collect device measurements from a selected monitoring device specified in the script program. Instep 314,microprocessor 102 prompts the individual to connect the selected device to one of the device jacks 96A, 96B, or 96C. A sample prompt is shown inFIG. 9 . Instep 316,microprocessor 102 waits until a reply to the prompt is received from the individual. When a reply is received,microprocessor 102 proceeds to step 318.Microprocessor 102 also connectsUART 104 todevice interface 118 throughCMOS switch 116. Instep 318,microprocessor 102 collects device measurements from the selected device throughdevice interface 118. The device measurements are stored inmemory 108. - In
step 320,microprocessor 102 prompts the individual to connectremote apparatus 60 totelephone jack 119 so that the apparatus may connect to the server at the prescribed connection time. Instep 322,microprocessor 102 waits until a reply to the prompt is received from the individual. When a reply is received,microprocessor 102 turns offLED 100 instep 324. Instep 326,microprocessor 102 waits until it is time to connect to the server.Microprocessor 102 compares the connection time specified in the script program to the current time output byclock 112. When it is time to connect,microprocessor 102 connectsDART 104 tomodem 114 throughCMOS switch 116. - In
step 328,microprocessor 102 establishes a subsequent communication link betweenremote apparatus 60 andserver 50 throughmodem 114 andcommunication network 58. If the connection fails for any reason,microprocessor 102 repeats step 328 to get a successful connection. Instep 330,microprocessor 102 transmits the query responses, device measurements, script identification code, and the individual's unique identification code stored inmemory 108 to the server. Instep 332,microprocessor 102 receives through modem 114 a newly assigned script program from the server. The new script program is stored inmemory 108 for subsequent execution bymicroprocessor 102. Followingstep 332, the script program ends. - After the individual's information has been collected via
remote apparatus 60 and the script programs, the data is mined to distinguish patterns. Data mining programs are well known in the art and can be easily adapted to this system. In the preferred embodiment, the data mining program includes a data table 150, as shown inFIG. 13 . Data table 150 is stored on the server and has an individualidentification number field 151, name fields 152, value fields 154 corresponding to the name fields, andexplanation fields 156 corresponding to the name fields and value fields. The data type is entered into name fields 152, the possible numerical values corresponding to the data type are entered intovalue fields 154, and brief explanations of the data types and corresponding values are entered into explanation fields 156. - The individuals' device measurements and responses to the queries are entered into data table 150 in the form of numerical values in value fields 154. The individual's identification number is entered into individual
identification number field 151. An example of data table 150 in which the individuals' information has been entered is shown inFIG. 14 . Once data table 150 contains all the necessary information, the data mining program then compares the information. -
FIG. 15 is a flowchart illustrating a first method of the present invention carried out by the server using the data mining techniques described above. Instep 400, individuals having a risk factor for a disease are selected. Instep 402, these individuals are queried about their behavior and environment using the script programs and remote apparatuses previously described. The responses to the queries and any device measurements are received and stored by the server. Collection of the responses and device measurements can occur over any period of time, thus allowing for more accurate data. - After the server receives the responses and measurements, a database comprising the individuals' behavioral and environmental profiles is created in
step 404. Instep 406, data mining techniques are used to group individuals having similar behavioral and environmental profiles. Instep 408, the server determines if it is necessary to further group the individuals in order to produce smaller groups.Steps - In
step 410, each group of individuals is categorized using data mining techniques. The individuals are categorized according to their disease progressions. For example, a group of individuals can be categorized into those that have a severe disease phenotype, those that have a moderate disease phenotype, and those that have a mild disease phenotype: Instep 412, the server determines if it is necessary to further categorize the individuals.Steps - In
step 414, the genomes of all the individuals are sequenced by genotypingsystem 56. The genotypes of all the individuals are transmitted toserver 50. Instep 416, data mining techniques are used to compare the genotypes of the individuals between the categories. For example, if those individuals who have a severe disease phenotype and are overweight have a certain gene sequence, while those individuals who have a mild disease phenotype and are overweight do not, it Is likely the gene sequence is responsible for the severe disease phenotype. If a gene sequence is found, it is further identified instep 418. Methods of isolating and identifying gene sequences are well known in the field. -
FIG. 16 is a block diagram illustrating an example of the first method of the present invention as described inFIG. 15 . First individuals having a risk factor for a certain disease, such as is non-insulin dependent diabetes mellitus (NIDDM), are selected, as indicated atblock 422. Behavioral and environmental information from each individual is collected using the script programs and remote apparatuses. Using data mining techniques, the individuals are then grouped intooverweight individuals 424 andnon-overweight individuals 426. Using- data mining techniques, the individuals are then categorized into overweight individuals havingsevere NIDDM 428, overweight individuals havingmild NIDDM 430, non-overweight individuals havingmild NIDDM 432, and non-overweight individuals havingsevere NIDDM 434. - The individuals' genotype information is then taken, as indicated at
block 436, to determine the individuals' gene sequences. For example, overweight individuals with severe NIDDM have gene sequence A, overweight individuals with mild NIDDM have gene sequence B, non-overweight individuals with mild NIDDM have gene sequence B, and non-overweight individuals with severe NIDDM have gene sequence A. Data mining techniques are then used to analyze the information and come to a conclusion. In this example, data mining would conclude that the severe NIDDM phenotype is likely related to gene sequence A, not the individual's weight. -
FIG. 17 shows a flowchart illustrating a second method of the present invention carried out by the server using the data mining techniques described above. Instep 500, individuals having a risk factor for a disease are selected. Instep 502, these individuals are queried about their behavior and environment using the script programs and remote apparatuses previously described. The responses to the queries and any device measurements are received and stored by the server. - After the server receives the responses and measurements from the remote apparatuses, a database comprising the individuals' behavioral and environmental profiles is created in
step 504. Instep 506, data mining techniques are used to group together individuals having similar disease progressions. For example, a group of individuals can be grouped into those that have a severe disease phenotype, those that have a moderate disease phenotype, and those that have a mild disease phenotype. Instep 508, the server determines if it is necessary to further group the individuals in order to produce smaller groups.Steps - In
step 510, each group of individuals created insteps step 512, the server determines if it is necessary to further group the individuals in order to produce smaller groups.Steps - In
step 514, the genomes of all the individuals are sequenced by genotypingsystem 56. The genotypes of all the individuals are transmitted to the server. Instep 516, data mining techniques are used to compare the genotypes of the individuals between the categories. For example, if those individuals who have a severe disease phenotype and are overweight have a certain gene sequence, while those individuals who have a mild disease and are also overweight phenotype do riot, it is likely the gene sequence, not weight; is responsible for the severe disease phenotype. If a gene sequence is found, it is further identified instep 518. Specific techniques of isolating and identifying gene sequences are well known in the field. -
FIG. 18 is a block diagram illustrating an example of the second method of the present invention as described inFIG. 17 . First individuals having a risk factor for a certain disease, such as NIDDM, are chosen, as indicated atblock 522. Behavioral and environmental information from each individual is collected using the remote apparatuses and script programs. Using data mining techniques, the individuals are then grouped into those exhibitingsevere NIDDM 524 and those exhibiting mild NIDDM 525. Using data mining techniques, the individuals are then categorized into overweight individuals havingsevere NIDDM 528, non--overweight individuals havingsevere NIDDM 530, non-overweight individuals havingmild NIDDM 532, and overweight individuals havingmild NIDDM 534. - The individuals' genotype information is then taken, as indicated at block 535, to determine the individuals gene sequences. For example, individuals with severe NIDDM who are overweight have gene sequence A, individuals with severe NIDDM who are non-overweight have gene sequence A, individuals with mild NIDDM who are non-overweight have gene sequence B, and individuals with severe NIDDM who are overweight have gene sequence B. Data mining techniques are then used to analyze the information and come to a conclusion. In this example, data mining would conclude that the severe NIDDM phenotype is likely related to gene sequence A, not the individual's weight.
-
FIG. 19 shows a flowchart illustrating a preferred method carried out byserver 50 to identify a disease-identifying substance. Instep 600, individuals having a risk factor for a disease are selected. Instep 602, these individuals are queried about their behavior and environment using the script programs and remote apparatuses previously described. The responses to the queries and any device measurements are received and stored by the server. - After the server receives the responses and measurements from the remote apparatuses, a database comprising the individuals' behavioral and environmental profiles is created in
step 604. Instep 606, the genomes of all the individuals are sequenced, and the genotypes of all the individuals are transmitted to the server. Instep 608, individuals having the sake or close genotypes are grouped together. Instep 610, data mining techniques are used to categorize together individuals having similar disease progressions. Instep 612, the server determines if it is necessary to further categorize the individuals in order to produce smaller groups.Steps - In
step 614, data mining techniques are used to find a disease-influencing substance between the categories of individuals by using the individuals behavioral and environmental profiles. For example, if those individuals who have a severe disease phenotype are overweight, while those individuals who have a mild disease phenotype are not, it is likely weight is responsible for the severe disease phenotype. If such a disease-influencing substance is found, it is identified in step 618. If no disease-influencing substance is found, the process is preferably repeated. -
FIG. 20 is a block diagram illustrating an example of the method described inFIG. 19 . First, individuals having a risk factor for a certain disease, such as NIDDM, are chosen, as indicated atblock 620. Behavioral and environmental information from each individual is collected using the remote apparatuses and script programs. The individuals' genotype information is then taken, as indicated atblock 622, to determine the individuals' gene sequences. The individuals are then grouped according to their gene sequences. For example, one group may have gene sequence A, as indicated atblock 624, while another group may have gene sequence B, as indicated atblock 626. Using data mining techniques, the individuals are then categorized into individuals with gene sequence A havingsevere NIDDM 628, individuals with gene sequence A havingmild NIDDM 630, individuals with gene sequence B havingmild NIDDM 632, and individuals with gene sequence B havingsevere NIDDM 634. - Data mining techniques are further used to analyze the categories of individuals and their behavioral and environmental profiles. For example,
overweight individuals 638 with severe NIDDM have gene sequence A,non-overweight individuals 640 with mild NIDDM have gene sequence A,overweight individuals 642 with mild NIDDM have gene sequence B, andnon-overweight individuals 644 with severe NIDDM have gene sequence B. Data mining techniques are then used to analyze the information and come to a conclusion. In this example, data mining would conclude that the severe NIDDM phenotype is likely related to gene sequence A, not the individual's weight. - Although the above description contains many specificities, these should not be construed as limitations on the scope of the invention but merely as illustrations of some of the presently preferred embodiments. Many other embodiments of the invention are possible. For example, the scripting language and script commands shown are representative of the preferred embodiment. It will be apparent to one skilled in the art that many other scripting languages and specific script commands may be used to implement the invention.
- Moreover, the invention is not limited to the specific applications described. The system and method of the invention have many other applications. For example, pharmaceutical manufacturers may apply the system in clinical trials to analyze new drug data.
- Therefore, the scope of the invention should be determined by the appended claims and their legal equivalents.
Claims (17)
1. A method for generating groups of individuals useful in researching influence of a disease on said individuals, comprising:
selecting individuals having a risk factor for a disease;
providing to each individual a communications apparatus;
transmitting a computer program containing queries and predefined response choices to said communications apparatus, wherein said computer program when executed causes said communications apparatus to present said queries and predefined response choices to each individual via a touch sensitive display of said communications apparatus and collect responses to said queries, including at least one of the predefined response choices presented on the display of the communications apparatus, from each individual via said touch sensitive display of the communications apparatus;
receiving said responses to the queries from the individuals through the apparatus, said responses communicating information about the individuals;
storing the responses of each individual in a database;
defining a plurality of groups by categorizing the individuals having similar profiles based on the responses, wherein categorizing the individuals into groups includes one or more phenotypic classifications;
after defining said groups, receiving genotype information representative of individuals in each of said groups;
comparing said genotype information between said groups; and
generating a report for presentation on a display that represents a subset of said genotype information associated with each of said groups, wherein differences in said genotype information between said groups is expressed in terms of phenotypic classifications.
2. The method according to claim 1 , wherein the queries are inserted into said computer program with a script generator and assigned to an individual using a script assignor.
3. The method according to claim 1 , wherein the one or more phenotypic classifications comprise one or more of behavioral, environmental, and disease progression.
4. The method according to claim 1 , wherein the communication apparatus is connectable with a monitoring device configured to acquire physiologic data.
5. The method according to claim 4 , wherein the monitoring device includes one of the set consisting of a blood glucose meter, a respiratory flow meter, a blood pressure cuff, a weight scale, and a pulse rate monitor.
6. The method according claim 1 , wherein the responses to the queries from the individuals communicate environmental information about the individuals.
7. The method according claim 6 , wherein the environmental information comprises one or more of non-genetic information about an individual, information about disease progression, information about diet, information about lifestyle, and information about geographical location.
8. The method according claim 1 , wherein the queries contained in said computer program are related to one or both of behavior and environment of each individual.
9. A system for generating groups of individuals useful in researching influence of a disease on said individuals, comprising:
a communications apparatus operable by an individual; and
a communication network in signal communication with the communications apparatus and a server, a workstation configured to send scripted queries and predefined response choices, a genotyping system configured to provide genotype information representative of the individual, and a patient profile system configured to receive responses from the individual and genotype information analyses via the communications network and the server, wherein the server transmits a computer program containing the scripted queries and predefined response choices to the communications apparatus, the computer program when executed causes the communications apparatus to present the scripted queries and predefined response choices to the individual via a touch sensitive display of said communications apparatus and collect responses to the queries containing information about the individual and at least one of the predefined response choices presented on the touch sensitive display of said communications apparatus,
wherein the genotype information is compared based upon groups formed by categorizing individuals having a risk factor for a disease using the responses to the scripted queries in the patient profile system to identify one or more individuals having similar profiles, wherein categorizing the individuals into groups includes one or more phenotypic classifications, and differences in said genotype information between said groups is expressed in terms of phenotypic classifications.
10. The system according claim 9 , wherein the responses from the individual are used to categorize the individual into one or more groups and the one or more groups are compared with the genotype information of the individual to categorize said genotype information according to disease progression.
11. The system according claim 10 , wherein the disease progression includes non-insulin dependent diabetes.
12. The system according claim 9 , wherein the one or more phenotypic classifications comprise one or more of behavioral, environmental, and disease progression.
13. A system for identifying groups of individuals useful in researching influence of disease on said individuals, comprising:
at least one communications apparatus in signal communication with a monitoring device configured to measure physiologic and environmental conditions, the communications apparatus and monitoring device being operable by at least one individual; and
a communication network in signal communications with each communications apparatus and a server, a workstation configured to send scripted queries and predefined response choices, a genotyping system configured to provide genotype information representative of the at least one individual, and a patient profile system configured to receive responses and measurements from the at least one individual and genotype information analyses via the communications network and the server, wherein the server transmits a computer program containing the scripted queries and predefined response choices to the communication apparatus, the computer program when executed causes the communication apparatus to present the scripted queries and predefined response choices to the individual via a touch sensitive display of the communications apparatus and collect responses to the queries containing information about the individual and at least one of the predefined response choices presented on the touch sensitive display of said communications apparatus,
wherein the genotype information representative of the at least one individual is compared based upon groups formed by categorizing individuals having a risk factor for a disease using the responses and measurements to the scripted queries in the patient profile system to identify one or more individuals having similar profiles, wherein categorizing the individuals into groups includes one or more phenotypic classifications, and differences in said genotype information between said groups is expressed in terms of phenotypic classifications.
14. The system according claim 13 , wherein the monitoring device includes one of the set consisting of a blood glucose meter, a respiratory flow meter, a blood pressure cuff, a weight scale, and a pulse rate monitor.
15. The system according claim 13 , wherein the responses and measurements from each individual are used to categorized each individual with one or more groups and the groups are compared with the genotype information representative of each individual to categorize the genotype information according to disease progression of each individual in the one or more groups based on the responses and measurements sent by each individual.
16. The system according claim 15 , wherein the disease progression includes non-insulin dependent diabetes.
17. The system according claim 13 , wherein the one or more phenotypic classifications comprise one or more of behavioral, environmental, and disease progression.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/408,334 US20120203466A1 (en) | 1997-03-28 | 2012-02-29 | System and method for identifying disease-influencing genes |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4175197P | 1997-03-28 | 1997-03-28 | |
US4174697P | 1997-03-28 | 1997-03-28 | |
US09/496,893 US8078407B1 (en) | 1997-03-28 | 2000-02-02 | System and method for identifying disease-influencing genes |
US13/303,622 US20120130647A1 (en) | 1997-03-28 | 2011-11-23 | System and method for identifying disease-influencing genes |
US13/408,334 US20120203466A1 (en) | 1997-03-28 | 2012-02-29 | System and method for identifying disease-influencing genes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/303,622 Continuation US20120130647A1 (en) | 1997-03-28 | 2011-11-23 | System and method for identifying disease-influencing genes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120203466A1 true US20120203466A1 (en) | 2012-08-09 |
Family
ID=46087692
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/847,009 Expired - Lifetime US5897493A (en) | 1992-11-17 | 1997-04-30 | Monitoring system for remotely querying individuals |
US13/303,622 Abandoned US20120130647A1 (en) | 1997-03-28 | 2011-11-23 | System and method for identifying disease-influencing genes |
US13/408,334 Abandoned US20120203466A1 (en) | 1997-03-28 | 2012-02-29 | System and method for identifying disease-influencing genes |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/847,009 Expired - Lifetime US5897493A (en) | 1992-11-17 | 1997-04-30 | Monitoring system for remotely querying individuals |
US13/303,622 Abandoned US20120130647A1 (en) | 1997-03-28 | 2011-11-23 | System and method for identifying disease-influencing genes |
Country Status (1)
Country | Link |
---|---|
US (3) | US5897493A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8996392B2 (en) | 2011-03-31 | 2015-03-31 | Healthspot, Inc. | Medical kiosk and method of use |
US9043217B2 (en) | 2011-03-31 | 2015-05-26 | HealthSpot Inc. | Medical kiosk and method of use |
US10223681B2 (en) | 2012-08-15 | 2019-03-05 | Rite Aid Hdqtrs. Corp. | Veterinary kiosk with integrated veterinary medical devices |
Families Citing this family (582)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6241704B1 (en) | 1901-11-22 | 2001-06-05 | Sims Deltec, Inc. | Drug pump systems and methods |
US6330426B2 (en) | 1994-05-23 | 2001-12-11 | Stephen J. Brown | System and method for remote education using a memory card |
US8712790B1 (en) * | 1997-03-28 | 2014-04-29 | Robert Bosch Gmbh | Multi-user remote health monitoring system with biometrics support |
WO2001037174A1 (en) * | 1992-11-17 | 2001-05-25 | Health Hero Network, Inc. | Method and system for improving adherence with a diet program or other medical regimen |
US7941326B2 (en) * | 2001-03-14 | 2011-05-10 | Health Hero Network, Inc. | Interactive patient communication development system for reporting on patient healthcare management |
US8027809B2 (en) | 1992-11-17 | 2011-09-27 | Health Hero Network, Inc. | Home power management system |
US8626521B2 (en) * | 1997-11-21 | 2014-01-07 | Robert Bosch Healthcare Systems, Inc. | Public health surveillance system |
US5951300A (en) | 1997-03-10 | 1999-09-14 | Health Hero Network | Online system and method for providing composite entertainment and health information |
US5832448A (en) | 1996-10-16 | 1998-11-03 | Health Hero Network | Multiple patient monitoring system for proactive health management |
US9215979B2 (en) | 1992-11-17 | 2015-12-22 | Robert Bosch Healthcare Systems, Inc. | Multi-user remote health monitoring system |
US20030212579A1 (en) * | 2002-05-08 | 2003-11-13 | Brown Stephen J. | Remote health management system |
US7624028B1 (en) * | 1992-11-17 | 2009-11-24 | Health Hero Network, Inc. | Remote health monitoring and maintenance system |
US8078431B2 (en) | 1992-11-17 | 2011-12-13 | Health Hero Network, Inc. | Home power management system |
US20010011224A1 (en) | 1995-06-07 | 2001-08-02 | Stephen James Brown | Modular microprocessor-based health monitoring system |
US6968375B1 (en) | 1997-03-28 | 2005-11-22 | Health Hero Network, Inc. | Networked system for interactive communication and remote monitoring of individuals |
US5307263A (en) | 1992-11-17 | 1994-04-26 | Raya Systems, Inc. | Modular microprocessor-based health monitoring system |
US6196970B1 (en) | 1999-03-22 | 2001-03-06 | Stephen J. Brown | Research data collection and analysis |
US8078407B1 (en) | 1997-03-28 | 2011-12-13 | Health Hero Network, Inc. | System and method for identifying disease-influencing genes |
US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
US8095340B2 (en) | 1992-11-17 | 2012-01-10 | Health Hero Network, Inc. | Home power management system |
US7970620B2 (en) * | 1992-11-17 | 2011-06-28 | Health Hero Network, Inc. | Multi-user remote health monitoring system with biometrics support |
USRE43433E1 (en) | 1993-12-29 | 2012-05-29 | Clinical Decision Support, Llc | Computerized medical diagnostic and treatment advice system |
US5935060A (en) * | 1996-07-12 | 1999-08-10 | First Opinion Corporation | Computerized medical diagnostic and treatment advice system including list based processing |
US5660176A (en) * | 1993-12-29 | 1997-08-26 | First Opinion Corporation | Computerized medical diagnostic and treatment advice system |
US6206829B1 (en) | 1996-07-12 | 2001-03-27 | First Opinion Corporation | Computerized medical diagnostic and treatment advice system including network access |
US8015033B2 (en) | 1994-04-26 | 2011-09-06 | Health Hero Network, Inc. | Treatment regimen compliance and efficacy with feedback |
US5836312A (en) * | 1996-01-02 | 1998-11-17 | Moore; Steven Jerome | Computer-assisted system and method for adjudging the effect of consumable intakes on physiological parameters |
US7305348B1 (en) * | 1996-02-20 | 2007-12-04 | Health Hero Network, Inc. | Aggregating and pooling health related information in a communication system with feedback |
US6050940A (en) * | 1996-06-17 | 2000-04-18 | Cybernet Systems Corporation | General-purpose medical instrumentation |
US8079953B2 (en) | 1996-06-17 | 2011-12-20 | Cybernet Systems Corporation | General-purpose medical instrumentation |
TWI249760B (en) * | 1996-07-31 | 2006-02-21 | Canon Kk | Remote maintenance system |
US6032119A (en) | 1997-01-16 | 2000-02-29 | Health Hero Network, Inc. | Personalized display of health information |
US6234964B1 (en) * | 1997-03-13 | 2001-05-22 | First Opinion Corporation | Disease management system and method |
US6139494A (en) * | 1997-10-15 | 2000-10-31 | Health Informatics Tools | Method and apparatus for an integrated clinical tele-informatics system |
US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6102970A (en) * | 1998-03-27 | 2000-08-15 | Davox Corporation | System and method for optimizing a program containing a number of the flows through flow branches |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8882666B1 (en) | 1998-05-08 | 2014-11-11 | Ideal Life Inc. | Personal health monitoring and/or communication system |
WO1999063901A1 (en) * | 1998-06-08 | 1999-12-16 | Glaxo Group Limited | Disease management/training system and method |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6558320B1 (en) * | 2000-01-20 | 2003-05-06 | Medtronic Minimed, Inc. | Handheld personal data assistant (PDA) with a medical device and method of using the same |
US20080004915A1 (en) | 1998-09-25 | 2008-01-03 | Brown Stephen J | Dynamic modeling and scoring risk assessment |
WO2000025192A2 (en) * | 1998-10-26 | 2000-05-04 | Visionary Medical, Inc. | Prescription-controlled data collection system and method |
US6149585A (en) * | 1998-10-28 | 2000-11-21 | Sage Health Management Solutions, Inc. | Diagnostic enhancement method and apparatus |
US6528856B1 (en) * | 1998-12-15 | 2003-03-04 | Intel Corporation | High dielectric constant metal oxide gate dielectrics |
US20050086082A1 (en) * | 1999-01-21 | 2005-04-21 | Patient Care Technologies | Portable health assistant |
US7555470B2 (en) * | 1999-03-22 | 2009-06-30 | Health Hero Network, Inc. | Research data collection and analysis |
US20040220829A1 (en) * | 1999-03-22 | 2004-11-04 | Ofir Baharav | Distributed system and method for managing communication among healthcare providers, patients and third parties |
US7577475B2 (en) * | 1999-04-16 | 2009-08-18 | Cardiocom | System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus |
US7945451B2 (en) * | 1999-04-16 | 2011-05-17 | Cardiocom, Llc | Remote monitoring system for ambulatory patients |
US6290646B1 (en) * | 1999-04-16 | 2001-09-18 | Cardiocom | Apparatus and method for monitoring and communicating wellness parameters of ambulatory patients |
US6755783B2 (en) | 1999-04-16 | 2004-06-29 | Cardiocom | Apparatus and method for two-way communication in a device for monitoring and communicating wellness parameters of ambulatory patients |
US8438038B2 (en) * | 1999-04-16 | 2013-05-07 | Cardiocom, Llc | Weight loss or weight management system |
US20070021979A1 (en) * | 1999-04-16 | 2007-01-25 | Cosentino Daniel L | Multiuser wellness parameter monitoring system |
US20060030890A1 (en) * | 1999-04-16 | 2006-02-09 | Cosentino Daniel L | System, method, and apparatus for automated interactive verification of an alert generated by a patient monitoring device |
US8419650B2 (en) * | 1999-04-16 | 2013-04-16 | Cariocom, LLC | Downloadable datasets for a patient monitoring system |
US20080201168A1 (en) * | 1999-05-03 | 2008-08-21 | Brown Stephen J | Treatment regimen compliance and efficacy with feedback |
US6312378B1 (en) * | 1999-06-03 | 2001-11-06 | Cardiac Intelligence Corporation | System and method for automated collection and analysis of patient information retrieved from an implantable medical device for remote patient care |
US6607485B2 (en) | 1999-06-03 | 2003-08-19 | Cardiac Intelligence Corporation | Computer readable storage medium containing code for automated collection and analysis of patient information retrieved from an implantable medical device for remote patient care |
US6270457B1 (en) | 1999-06-03 | 2001-08-07 | Cardiac Intelligence Corp. | System and method for automated collection and analysis of regularly retrieved patient information for remote patient care |
US7134996B2 (en) | 1999-06-03 | 2006-11-14 | Cardiac Intelligence Corporation | System and method for collection and analysis of patient information for automated remote patient care |
US7429243B2 (en) * | 1999-06-03 | 2008-09-30 | Cardiac Intelligence Corporation | System and method for transacting an automated patient communications session |
US6221011B1 (en) | 1999-07-26 | 2001-04-24 | Cardiac Intelligence Corporation | System and method for determining a reference baseline of individual patient status for use in an automated collection and analysis patient care system |
CA2314513A1 (en) * | 1999-07-26 | 2001-01-26 | Gust H. Bardy | System and method for providing normalized voice feedback from an individual patient in an automated collection and analysis patient care system |
CA2314517A1 (en) * | 1999-07-26 | 2001-01-26 | Gust H. Bardy | System and method for determining a reference baseline of individual patient status for use in an automated collection and analysis patient care system |
ES2574232T3 (en) | 1999-08-05 | 2016-06-16 | Resmed R&D Germany Gmbh | Device for supplying respiratory air, humidification device, respiratory gas tube and connection device for it |
WO2001024098A2 (en) * | 1999-09-13 | 2001-04-05 | Healinx | A message and program system supporting communication |
US6454705B1 (en) | 1999-09-21 | 2002-09-24 | Cardiocom | Medical wellness parameters management system, apparatus and method |
WO2001028416A1 (en) | 1999-09-24 | 2001-04-26 | Healthetech, Inc. | Physiological monitor and associated computation, display and communication unit |
US6535523B1 (en) * | 1999-09-30 | 2003-03-18 | Qualcomm Incorporated | System and method for persistence vector based rate assignment |
US6527711B1 (en) * | 1999-10-18 | 2003-03-04 | Bodymedia, Inc. | Wearable human physiological data sensors and reporting system therefor |
US6648820B1 (en) | 1999-10-27 | 2003-11-18 | Home-Medicine (Usa), Inc. | Medical condition sensing system |
US6411840B1 (en) | 1999-11-16 | 2002-06-25 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation |
US6398728B1 (en) * | 1999-11-16 | 2002-06-04 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring respiratory insufficiency and outcomes thereof |
US6368284B1 (en) * | 1999-11-16 | 2002-04-09 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring myocardial ischemia and outcomes thereof |
US6440066B1 (en) | 1999-11-16 | 2002-08-27 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for ordering and prioritizing multiple health disorders to identify an index disorder |
US8369937B2 (en) | 1999-11-16 | 2013-02-05 | Cardiac Pacemakers, Inc. | System and method for prioritizing medical conditions |
US6336903B1 (en) * | 1999-11-16 | 2002-01-08 | Cardiac Intelligence Corp. | Automated collection and analysis patient care system and method for diagnosing and monitoring congestive heart failure and outcomes thereof |
US6829478B1 (en) | 1999-11-19 | 2004-12-07 | Pamela G. Layton | Information management network for automated delivery of alarm notifications and other information |
US6442432B2 (en) | 1999-12-21 | 2002-08-27 | Medtronic, Inc. | Instrumentation and software for remote monitoring and programming of implantable medical devices (IMDs) |
US6980958B1 (en) * | 2000-01-11 | 2005-12-27 | Zycare, Inc. | Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients |
US20020068857A1 (en) | 2000-02-14 | 2002-06-06 | Iliff Edwin C. | Automated diagnostic system and method including reuse of diagnostic objects |
US20030060765A1 (en) * | 2000-02-16 | 2003-03-27 | Arthur Campbell | Infusion device menu structure and method of using the same |
US7379885B1 (en) * | 2000-03-10 | 2008-05-27 | David S. Zakim | System and method for obtaining, processing and evaluating patient information for diagnosing disease and selecting treatment |
AU2001247534A1 (en) * | 2000-03-15 | 2001-09-24 | Health Hero Network, Inc. | An interactive patient communication development system for reporting on patienthealthcare management |
WO2002041227A1 (en) * | 2000-03-21 | 2002-05-23 | Health Hero Network, Inc. | Networked system for interactive communication and remote monitoring of individuals |
WO2001077986A2 (en) * | 2000-04-05 | 2001-10-18 | The Johns Hopkins University | Automated risk management infrastructure for healthcare |
WO2001088810A1 (en) * | 2000-05-12 | 2001-11-22 | Opsion Medical, Inc. | Networked medical information system for clinical practices |
US6482158B2 (en) | 2000-05-19 | 2002-11-19 | Healthetech, Inc. | System and method of ultrasonic mammography |
NZ523260A (en) * | 2000-06-02 | 2005-10-28 | Quality Metric | Method and system for health assessment and monitoring |
US7818185B2 (en) * | 2000-06-02 | 2010-10-19 | Qualitymetric Incorporated | Method, system and medium for assessing the impact of various ailments on health related quality of life |
US6605038B1 (en) | 2000-06-16 | 2003-08-12 | Bodymedia, Inc. | System for monitoring health, wellness and fitness |
WO2005029242A2 (en) | 2000-06-16 | 2005-03-31 | Bodymedia, Inc. | System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability |
US20060122474A1 (en) * | 2000-06-16 | 2006-06-08 | Bodymedia, Inc. | Apparatus for monitoring health, wellness and fitness |
US7689437B1 (en) * | 2000-06-16 | 2010-03-30 | Bodymedia, Inc. | System for monitoring health, wellness and fitness |
US20020016719A1 (en) * | 2000-06-19 | 2002-02-07 | Nemeth Louis G. | Methods and systems for providing medical data to a third party in accordance with configurable distribution parameters |
DE60119100T2 (en) * | 2000-06-23 | 2006-08-31 | Bodymedia, Inc. | SYSTEM FOR THE MONITORING OF HEALTH, WELL-BEING AND CONDITION |
ES2329547T3 (en) * | 2000-06-30 | 2009-11-27 | Becton Dickinson And Company | MANAGEMENT NETWORK OF HEALTH LINKS AND DISEASES TO PROVIDE BETTER PATIENT ASSISTANCE. |
US6949073B2 (en) * | 2002-10-03 | 2005-09-27 | Home-Medicine.Com, Inc. | Dyspnea monitor, and telemedicine system and method |
US8043224B2 (en) * | 2000-07-12 | 2011-10-25 | Dimicine Research It, Llc | Telemedicine system |
US20030028399A1 (en) * | 2000-09-25 | 2003-02-06 | Duane Davis | Method and system for providing interactive health care services |
US7379964B1 (en) * | 2000-10-26 | 2008-05-27 | Union Hospital, Inc. | Method of facilitating medical consultations |
US6607387B2 (en) | 2000-10-30 | 2003-08-19 | Healthetech, Inc. | Sensor system for diagnosing dental conditions |
US20020055857A1 (en) * | 2000-10-31 | 2002-05-09 | Mault James R. | Method of assisting individuals in lifestyle control programs conducive to good health |
DE10057832C1 (en) | 2000-11-21 | 2002-02-21 | Hartmann Paul Ag | Blood analysis device has syringe mounted in casing, annular mounting carrying needles mounted behind test strip and being swiveled so that needle can be pushed through strip and aperture in casing to take blood sample |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US7054758B2 (en) * | 2001-01-30 | 2006-05-30 | Sciona Limited | Computer-assisted means for assessing lifestyle risk factors |
ES2599753T3 (en) | 2001-02-16 | 2017-02-03 | Resmed Limited | Humidifier with structure to prevent liquid reflux through the humidifier inlet |
US7835925B2 (en) | 2001-02-20 | 2010-11-16 | The Procter & Gamble Company | System for improving the management of the health of an individual and related methods |
US7232220B2 (en) * | 2001-03-01 | 2007-06-19 | Richard Franz | System for vision examination utilizing telemedicine |
US6595929B2 (en) | 2001-03-30 | 2003-07-22 | Bodymedia, Inc. | System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US20040030577A1 (en) * | 2001-04-05 | 2004-02-12 | Bitman William R. | Automated risk management infrastructure for healthcare |
US6635015B2 (en) | 2001-04-20 | 2003-10-21 | The Procter & Gamble Company | Body weight management system |
JP4498636B2 (en) | 2001-04-27 | 2010-07-07 | 日本サーモスタット株式会社 | Thermostat device |
JP4681795B2 (en) | 2001-05-18 | 2011-05-11 | デカ・プロダクツ・リミテッド・パートナーシップ | Fluid pump infusion set |
US8034026B2 (en) | 2001-05-18 | 2011-10-11 | Deka Products Limited Partnership | Infusion pump assembly |
US20030036923A1 (en) * | 2001-05-18 | 2003-02-20 | Waldon R. Forrest | Patient compliance and monitoring system |
US7103578B2 (en) * | 2001-05-25 | 2006-09-05 | Roche Diagnostics Operations, Inc. | Remote medical device access |
US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
AU2002348683A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
EP1404232B1 (en) | 2001-06-12 | 2009-12-02 | Pelikan Technologies Inc. | Blood sampling apparatus and method |
US7316700B2 (en) | 2001-06-12 | 2008-01-08 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
WO2002100460A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Electric lancet actuator |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
ES2357887T3 (en) | 2001-06-12 | 2011-05-03 | Pelikan Technologies Inc. | APPARATUS FOR IMPROVING THE BLOOD OBTAINING SUCCESS RATE FROM A CAPILLARY PUNCTURE. |
AU2002321885A1 (en) | 2001-08-03 | 2003-02-24 | Hill-Rom Services, Inc. | Patient point-of-care computer system |
US6781522B2 (en) | 2001-08-22 | 2004-08-24 | Kivalo, Inc. | Portable storage case for housing a medical monitoring device and an associated method for communicating therewith |
US6840904B2 (en) * | 2001-10-11 | 2005-01-11 | Jason Goldberg | Medical monitoring device and system |
US20030129578A1 (en) * | 2001-10-26 | 2003-07-10 | Mault James R. | Method and system for early detection of infectious diseases or symptoms of bioterrorism attacks |
WO2003048919A1 (en) * | 2001-11-30 | 2003-06-12 | Becton, Dickinson And Company | Medication adherence system |
US6985870B2 (en) | 2002-01-11 | 2006-01-10 | Baxter International Inc. | Medication delivery system |
US7034691B1 (en) * | 2002-01-25 | 2006-04-25 | Solvetech Corporation | Adaptive communication methods and systems for facilitating the gathering, distribution and delivery of information related to medical care |
US20030141981A1 (en) * | 2002-01-29 | 2003-07-31 | Tuan Bui | System and method for operating medical devices |
US10173008B2 (en) | 2002-01-29 | 2019-01-08 | Baxter International Inc. | System and method for communicating with a dialysis machine through a network |
US8775196B2 (en) | 2002-01-29 | 2014-07-08 | Baxter International Inc. | System and method for notification and escalation of medical data |
US8250483B2 (en) | 2002-02-28 | 2012-08-21 | Smiths Medical Asd, Inc. | Programmable medical infusion pump displaying a banner |
US8504179B2 (en) | 2002-02-28 | 2013-08-06 | Smiths Medical Asd, Inc. | Programmable medical infusion pump |
US20030192688A1 (en) * | 2002-04-10 | 2003-10-16 | Thomson Michael A. | Tubing saver rotator and method for using same |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7481776B2 (en) | 2002-04-19 | 2009-01-27 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7232451B2 (en) * | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8234128B2 (en) | 2002-04-30 | 2012-07-31 | Baxter International, Inc. | System and method for verifying medical device operational parameters |
US20030221687A1 (en) * | 2002-05-09 | 2003-12-04 | William Kaigler | Medication and compliance management system and method |
US20030236450A1 (en) * | 2002-06-24 | 2003-12-25 | Kocinski Richard J. | System for remotely monitoring and controlling CPAP apparatus |
US20040068230A1 (en) * | 2002-07-24 | 2004-04-08 | Medtronic Minimed, Inc. | System for providing blood glucose measurements to an infusion device |
US7278983B2 (en) | 2002-07-24 | 2007-10-09 | Medtronic Minimed, Inc. | Physiological monitoring device for controlling a medication infusion device |
US7020508B2 (en) | 2002-08-22 | 2006-03-28 | Bodymedia, Inc. | Apparatus for detecting human physiological and contextual information |
US20090177068A1 (en) * | 2002-10-09 | 2009-07-09 | Stivoric John M | Method and apparatus for providing derived glucose information utilizing physiological and/or contextual parameters |
DK1551282T3 (en) | 2002-10-09 | 2016-02-22 | Bodymedia Inc | DEVICE FOR RECEIVING, RECEIVING, DETERMINING AND DISPLAYING PHYSIOLOGICAL AND CONTEXTUAL INFORMATION ON A HUMAN |
US20030126593A1 (en) * | 2002-11-04 | 2003-07-03 | Mault James R. | Interactive physiological monitoring system |
US7890341B2 (en) * | 2002-12-09 | 2011-02-15 | Baxter International Inc. | System and a method for providing integrated access management for peritoneal dialysis and hemodialysis |
US20040111293A1 (en) * | 2002-12-09 | 2004-06-10 | Catherine Firanek | System and a method for tracking patients undergoing treatment and/or therapy for renal disease |
US7009511B2 (en) | 2002-12-17 | 2006-03-07 | Cardiac Pacemakers, Inc. | Repeater device for communications with an implantable medical device |
US20040122353A1 (en) * | 2002-12-19 | 2004-06-24 | Medtronic Minimed, Inc. | Relay device for transferring information between a sensor system and a fluid delivery system |
US7229288B2 (en) * | 2002-12-20 | 2007-06-12 | Medtronic Minimed, Inc. | Method, system, and program for using a virtual environment to provide information on using a product |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US7154398B2 (en) | 2003-01-06 | 2006-12-26 | Chen Thomas C H | Wireless communication and global location enabled intelligent health monitoring system |
US20060142648A1 (en) * | 2003-01-07 | 2006-06-29 | Triage Data Networks | Wireless, internet-based, medical diagnostic system |
US20050148882A1 (en) * | 2004-01-06 | 2005-07-07 | Triage Wireless, Incc. | Vital signs monitor used for conditioning a patient's response |
US7396330B2 (en) * | 2003-01-07 | 2008-07-08 | Triage Data Networks | Wireless, internet-based medical-diagnostic system |
US20040172284A1 (en) * | 2003-02-13 | 2004-09-02 | Roche Diagnostics Corporation | Information management system |
US7587287B2 (en) | 2003-04-04 | 2009-09-08 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
US7182738B2 (en) | 2003-04-23 | 2007-02-27 | Marctec, Llc | Patient monitoring apparatus and method for orthosis and other devices |
AU2003901956A0 (en) * | 2003-04-24 | 2003-05-15 | Anti Obeez City Pty Ltd | Game |
US7399276B1 (en) * | 2003-05-08 | 2008-07-15 | Health Hero Network, Inc. | Remote health monitoring system |
US7780595B2 (en) | 2003-05-15 | 2010-08-24 | Clinical Decision Support, Llc | Panel diagnostic method and system |
CA2525784C (en) * | 2003-05-16 | 2019-04-09 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
US20050038326A1 (en) * | 2003-05-30 | 2005-02-17 | Michael Mathur | System, device, and method for remote monitoring and servicing |
US20050010444A1 (en) * | 2003-06-06 | 2005-01-13 | Iliff Edwin C. | System and method for assisting medical diagnosis using an anatomic system and cause matrix |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
AU2003903139A0 (en) * | 2003-06-20 | 2003-07-03 | Resmed Limited | Breathable gas apparatus with humidifier |
DE202004021795U1 (en) | 2003-06-20 | 2011-02-10 | ResMed Ltd., Bella Vista | Breathing apparatus with humidifier |
US20050009191A1 (en) * | 2003-07-08 | 2005-01-13 | Swenson Kirk D. | Point of care information management system |
US8034294B1 (en) | 2003-07-15 | 2011-10-11 | Ideal Life, Inc. | Medical monitoring/consumables tracking device |
US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
US8571880B2 (en) * | 2003-08-07 | 2013-10-29 | Ideal Life, Inc. | Personal health management device, method and system |
US20050114182A1 (en) * | 2003-09-05 | 2005-05-26 | Randolph Robin L. | Method and apparatus for generating patient reminders |
KR101084554B1 (en) | 2003-09-12 | 2011-11-17 | 보디미디어 인코퍼레이티드 | Method and apparatus for measuring heart related parameters |
US20050066335A1 (en) * | 2003-09-23 | 2005-03-24 | Robert Aarts | System and method for exposing local clipboard functionality towards external applications |
US7756726B2 (en) * | 2003-09-25 | 2010-07-13 | International Business Machines Corporation | Secured medical sign-in |
WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
US20050278194A1 (en) * | 2003-10-07 | 2005-12-15 | Holland Geoffrey N | Medication management system |
US20060100907A1 (en) * | 2003-10-07 | 2006-05-11 | Holland Geoffrey N | Medication management system |
US7490021B2 (en) | 2003-10-07 | 2009-02-10 | Hospira, Inc. | Method for adjusting pump screen brightness |
US20060089854A1 (en) * | 2003-10-07 | 2006-04-27 | Holland Geoffrey N | Medication management system |
US9123077B2 (en) * | 2003-10-07 | 2015-09-01 | Hospira, Inc. | Medication management system |
US8065161B2 (en) | 2003-11-13 | 2011-11-22 | Hospira, Inc. | System for maintaining drug information and communicating with medication delivery devices |
US20060089855A1 (en) * | 2003-10-07 | 2006-04-27 | Holland Geoffrey N | Medication management system |
US7895053B2 (en) * | 2003-10-07 | 2011-02-22 | Hospira, Inc. | Medication management system |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US8029454B2 (en) * | 2003-11-05 | 2011-10-04 | Baxter International Inc. | High convection home hemodialysis/hemofiltration and sorbent system |
EP1680175B1 (en) * | 2003-11-06 | 2019-06-05 | LifeScan, Inc. | Drug delivery pen with event notification means |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
WO2005089103A2 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US7488290B1 (en) * | 2004-02-19 | 2009-02-10 | Cardiac Pacemakers, Inc. | System and method for assessing cardiac performance through transcardiac impedance monitoring |
US8025624B2 (en) * | 2004-02-19 | 2011-09-27 | Cardiac Pacemakers, Inc. | System and method for assessing cardiac performance through cardiac vibration monitoring |
US8954336B2 (en) | 2004-02-23 | 2015-02-10 | Smiths Medical Asd, Inc. | Server for medical device |
US20050192487A1 (en) * | 2004-02-27 | 2005-09-01 | Cosentino Louis C. | System for collection, manipulation, and analysis of data from remote health care devices |
US20050192514A1 (en) * | 2004-03-01 | 2005-09-01 | Kearby Gerald W. | Audiological treatment system and methods of using the same |
CA2560323C (en) | 2004-03-22 | 2014-01-07 | Bodymedia, Inc. | Non-invasive temperature monitoring device |
WO2005106758A2 (en) * | 2004-04-30 | 2005-11-10 | Koninklijke Philips Electronics, N.V. | Method for delivering subjective surveys linked to subjective and objective data |
US20060025931A1 (en) * | 2004-07-30 | 2006-02-02 | Richard Rosen | Method and apparatus for real time predictive modeling for chronically ill patients |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
EP1765194A4 (en) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Method and apparatus for a fluid sampling device |
WO2005119524A2 (en) | 2004-06-04 | 2005-12-15 | Therasense, Inc. | Diabetes care host-client architecture and data management system |
US20060093997A1 (en) * | 2004-06-12 | 2006-05-04 | Neurotone, Inc. | Aural rehabilitation system and a method of using the same |
WO2005124722A2 (en) * | 2004-06-12 | 2005-12-29 | Spl Development, Inc. | Aural rehabilitation system and method |
US8224669B2 (en) * | 2004-07-01 | 2012-07-17 | Anchor Holdings, Inc. | Chronic disease management system |
US7329226B1 (en) | 2004-07-06 | 2008-02-12 | Cardiac Pacemakers, Inc. | System and method for assessing pulmonary performance through transthoracic impedance monitoring |
US7311666B2 (en) | 2004-07-10 | 2007-12-25 | Trigeminal Solutions, Inc. | Apparatus for collecting information |
US9081879B2 (en) * | 2004-10-22 | 2015-07-14 | Clinical Decision Support, Llc | Matrix interface for medical diagnostic and treatment advice system and method |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US8165893B1 (en) * | 2005-02-16 | 2012-04-24 | Ideal Life Inc. | Medical monitoring and coordinated care system |
US8618930B2 (en) * | 2005-03-11 | 2013-12-31 | Aframe Digital, Inc. | Mobile wireless customizable health and condition monitor |
US7616110B2 (en) * | 2005-03-11 | 2009-11-10 | Aframe Digital, Inc. | Mobile wireless customizable health and condition monitor |
US8378811B2 (en) * | 2005-03-11 | 2013-02-19 | Aframe Digital, Inc. | Mobile wireless customizable health and condition monitor |
US7495552B2 (en) * | 2005-04-15 | 2009-02-24 | Hewlett-Packard Development Company, L.P. | Prescription-customized medical hardware |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
US20060247504A1 (en) * | 2005-04-29 | 2006-11-02 | Honeywell International, Inc. | Residential monitoring system for selected parameters |
US20100063840A1 (en) * | 2005-05-03 | 2010-03-11 | Hoyme Kenneth P | System and method for managing coordination of collected patient data in an automated patient management system |
US8781847B2 (en) * | 2005-05-03 | 2014-07-15 | Cardiac Pacemakers, Inc. | System and method for managing alert notifications in an automated patient management system |
US20060253300A1 (en) * | 2005-05-03 | 2006-11-09 | Somberg Benjamin L | System and method for managing patient triage in an automated patient management system |
WO2006122741A2 (en) | 2005-05-17 | 2006-11-23 | Roche Diagnostics Gmbh | Host apparatus and method providing calibration and reagent information to a measurement apparatus which makes use of a consumable reagent in a measuring process |
GB2442620A (en) * | 2005-05-26 | 2008-04-09 | G W Pharma Ltd | A system for influencing and monitoring the movement of products |
US7881939B2 (en) * | 2005-05-31 | 2011-02-01 | Honeywell International Inc. | Monitoring system with speech recognition |
US8251904B2 (en) * | 2005-06-09 | 2012-08-28 | Roche Diagnostics Operations, Inc. | Device and method for insulin dosing |
US7405653B2 (en) * | 2005-06-13 | 2008-07-29 | Honeywell International Inc. | System for monitoring activities and location |
US9060681B2 (en) * | 2005-06-30 | 2015-06-23 | Honeywell International Inc. | Trend monitoring system with multiple access levels |
US20100270257A1 (en) * | 2005-07-13 | 2010-10-28 | Vitality, Inc. | Medicine Bottle Cap With Electronic Embedded Curved Display |
US20070016443A1 (en) * | 2005-07-13 | 2007-01-18 | Vitality, Inc. | Medication compliance systems, methods and devices with configurable and adaptable escalation engine |
US20090134181A1 (en) * | 2005-07-13 | 2009-05-28 | Vitality, Inc. | Medication dispenser with automatic refill |
US20070024439A1 (en) * | 2005-07-26 | 2007-02-01 | Tice Lee D | Monitoring system for a residence |
US20070073590A1 (en) * | 2005-08-22 | 2007-03-29 | Cosentino Louis C | Remote monitor for physiological parameters and durable medical supplies |
US7511623B2 (en) * | 2005-09-14 | 2009-03-31 | Honeywell International Inc. | In-residence monitoring system incorporating voice output |
CN101297296A (en) * | 2005-10-24 | 2008-10-29 | 皇家飞利浦电子股份有限公司 | Reflective education: a method for automated delivery of educational material linked to objective or subjective data |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US20080015422A1 (en) * | 2005-12-29 | 2008-01-17 | Guidance Interactive Healthcare, Inc. | Combined peripheral and health monitoring devices |
US20070179356A1 (en) * | 2005-12-29 | 2007-08-02 | Guidance Interactive Healthcare, Inc. | Programmable devices, systems and methods for encouraging the monitoring of medical parameters |
US11497846B2 (en) | 2006-02-09 | 2022-11-15 | Deka Products Limited Partnership | Patch-sized fluid delivery systems and methods |
US11027058B2 (en) | 2006-02-09 | 2021-06-08 | Deka Products Limited Partnership | Infusion pump assembly |
US11478623B2 (en) | 2006-02-09 | 2022-10-25 | Deka Products Limited Partnership | Infusion pump assembly |
WO2007095093A2 (en) | 2006-02-09 | 2007-08-23 | Deka Products Limited Partnership | Pumping fluid delivery systems and methods using force application assembly |
US11364335B2 (en) | 2006-02-09 | 2022-06-21 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US20080027292A1 (en) * | 2006-04-10 | 2008-01-31 | Rosman Paul M | Computer-Implemented Method and Apparatus for Diabetes Management |
US8073008B2 (en) * | 2006-04-28 | 2011-12-06 | Medtronic Minimed, Inc. | Subnetwork synchronization and variable transmit synchronization techniques for a wireless medical device network |
US20070255126A1 (en) * | 2006-04-28 | 2007-11-01 | Moberg Sheldon B | Data communication in networked fluid infusion systems |
US7942844B2 (en) * | 2006-04-28 | 2011-05-17 | Medtronic Minimed, Inc. | Remote monitoring for networked fluid infusion systems |
US20070253380A1 (en) * | 2006-04-28 | 2007-11-01 | James Jollota | Data translation device with nonvolatile memory for a networked medical device system |
US20070254593A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic Minimed, Inc. | Wireless data communication for a medical device network that supports a plurality of data communication modes |
US20070288266A1 (en) * | 2006-06-02 | 2007-12-13 | Suzanne Sysko | System and methods for chronic disease management and health assessment |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US8965707B2 (en) | 2006-08-03 | 2015-02-24 | Smiths Medical Asd, Inc. | Interface for medical infusion pump |
US8435206B2 (en) | 2006-08-03 | 2013-05-07 | Smiths Medical Asd, Inc. | Interface for medical infusion pump |
US8149131B2 (en) | 2006-08-03 | 2012-04-03 | Smiths Medical Asd, Inc. | Interface for medical infusion pump |
US8858526B2 (en) | 2006-08-03 | 2014-10-14 | Smiths Medical Asd, Inc. | Interface for medical infusion pump |
US8758238B2 (en) * | 2006-08-31 | 2014-06-24 | Health Hero Network, Inc. | Health related location awareness |
AU2007317669A1 (en) | 2006-10-16 | 2008-05-15 | Hospira, Inc. | System and method for comparing and utilizing activity information and configuration information from mulitple device management systems |
EP1918869A1 (en) * | 2006-11-02 | 2008-05-07 | Abb Research Ltd. | Dynamic safety balance monitoring |
RU2009120968A (en) * | 2006-11-03 | 2010-12-10 | Конинклейке Филипс Электроникс Н.В. (Nl) | INTEGRATED ASSESSMENTS, PERFORMANCE SEQUENCE AND REPORTING |
US8700431B2 (en) * | 2006-11-09 | 2014-04-15 | Koninklijke Philips N.V. | Care plan change propagation |
RU2461872C2 (en) * | 2006-11-09 | 2012-09-20 | Конинклейке Филипс Электроникс Н.В. | Meeting with patient governed by medical servicing network |
US8540517B2 (en) * | 2006-11-27 | 2013-09-24 | Pharos Innovations, Llc | Calculating a behavioral path based on a statistical profile |
US8540515B2 (en) * | 2006-11-27 | 2013-09-24 | Pharos Innovations, Llc | Optimizing behavioral change based on a population statistical profile |
US8672843B2 (en) * | 2006-11-27 | 2014-03-18 | Qtc Management, Inc. | Automated protocol for determining psychiatric disability |
US8540516B2 (en) * | 2006-11-27 | 2013-09-24 | Pharos Innovations, Llc | Optimizing behavioral change based on a patient statistical profile |
RU2009131455A (en) * | 2007-01-19 | 2011-02-27 | Конинклейке Филипс Электроникс Н.В. (Nl) | NETWORK CONFIGURATION USING A WIRELESS DEVICE |
WO2008087571A2 (en) * | 2007-01-19 | 2008-07-24 | Koninklijke Philips Electronics N.V. | Smart install |
US20080183500A1 (en) * | 2007-01-26 | 2008-07-31 | Banigan Michael H | Systems and processes for health management |
US8615408B2 (en) * | 2007-02-02 | 2013-12-24 | Koninklijke Philips N.V. | Interactive patient forums |
US20080319781A1 (en) * | 2007-02-16 | 2008-12-25 | Stivoric John M | Assessment and grouping applications of lifeotypes |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US10860943B2 (en) | 2007-02-22 | 2020-12-08 | WellDoc, Inc. | Systems and methods for disease control and management |
US9754077B2 (en) | 2007-02-22 | 2017-09-05 | WellDoc, Inc. | Systems and methods for disease control and management |
US10872686B2 (en) | 2007-02-22 | 2020-12-22 | WellDoc, Inc. | Systems and methods for disease control and management |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
JP2010534359A (en) * | 2007-03-08 | 2010-11-04 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Low cost system for audio / video content delivery to remote patients |
CN101627389A (en) * | 2007-03-08 | 2010-01-13 | 皇家飞利浦电子股份有限公司 | System and method for providing verbal and graphical instruction from a remote healthcare monitoring service helpdesk |
US20080228040A1 (en) * | 2007-03-16 | 2008-09-18 | Arthur Solomon Thompson | International medical expert diagnosis |
WO2008129482A2 (en) * | 2007-04-18 | 2008-10-30 | Koninklijke Philips Electronics, N.V. | Apparatus and methods for rendering personal stories to medical patients |
US8086552B2 (en) * | 2007-05-02 | 2011-12-27 | General Electric Company | Dynamic user prompting for pertinent clinical information |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US20080281165A1 (en) * | 2007-05-09 | 2008-11-13 | Raghu Rai | system and method for acquiring and transferring data to a remote server |
US20080300572A1 (en) * | 2007-06-01 | 2008-12-04 | Medtronic Minimed, Inc. | Wireless monitor for a personal medical device system |
US8365726B2 (en) | 2007-06-07 | 2013-02-05 | Resmed Limited | Tub for humidifier |
US20080319327A1 (en) * | 2007-06-25 | 2008-12-25 | Triage Wireless, Inc. | Body-worn sensor featuring a low-power processor and multi-sensor array for measuring blood pressure |
US20090177769A1 (en) * | 2007-08-10 | 2009-07-09 | Smiths Medical Md | Determining online status of a medical device |
US8560336B2 (en) | 2007-09-18 | 2013-10-15 | Humana Innovations Enterprises, Inc. | System and method for increasing compliance with a health plan |
US8326646B2 (en) * | 2007-09-18 | 2012-12-04 | Humana Innovations Enterprises, Inc. | Method and system for suggesting meals based on tastes and preferences of individual users |
US8463618B2 (en) | 2007-09-18 | 2013-06-11 | Humana Innovations Enterprises, Inc. | Method for tailoring strategy messages from an expert system to enhance success with modifications to health behaviors |
US20090075242A1 (en) * | 2007-09-18 | 2009-03-19 | Sensei, Inc. | System and method for automatically defining, creating, and managing meals |
US20090075781A1 (en) * | 2007-09-18 | 2009-03-19 | Sensei, Inc. | System for incorporating data from biometric devices into a feedback message to a mobile device |
US8655717B2 (en) * | 2007-09-18 | 2014-02-18 | Humana Innovations Enterprises, Inc. | System and method for rewarding users for changes in health behaviors |
US20090112626A1 (en) * | 2007-10-30 | 2009-04-30 | Cary Talbot | Remote wireless monitoring, processing, and communication of patient data |
US20090150877A1 (en) * | 2007-12-07 | 2009-06-11 | Roche Diagnostics Operations, Inc. | Data driven communication protocol grammar |
US9026370B2 (en) | 2007-12-18 | 2015-05-05 | Hospira, Inc. | User interface improvements for medical devices |
US8313467B2 (en) | 2007-12-27 | 2012-11-20 | Medtronic Minimed, Inc. | Reservoir pressure equalization systems and methods |
US9456955B2 (en) | 2007-12-31 | 2016-10-04 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US8881774B2 (en) | 2007-12-31 | 2014-11-11 | Deka Research & Development Corp. | Apparatus, system and method for fluid delivery |
US8900188B2 (en) | 2007-12-31 | 2014-12-02 | Deka Products Limited Partnership | Split ring resonator antenna adapted for use in wirelessly controlled medical device |
US10188787B2 (en) | 2007-12-31 | 2019-01-29 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US10080704B2 (en) | 2007-12-31 | 2018-09-25 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
CN104874047B (en) | 2007-12-31 | 2019-05-28 | 德卡产品有限公司 | It is transfused pump assembly |
EP3679969A3 (en) | 2007-12-31 | 2020-09-30 | DEKA Products Limited Partnership | Infusion pump assembly |
US20090240702A1 (en) | 2008-03-21 | 2009-09-24 | Computerized Screening, Inc. | Community based managed health kiosk and research database system |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US8133197B2 (en) | 2008-05-02 | 2012-03-13 | Smiths Medical Asd, Inc. | Display for pump |
NZ708912A (en) | 2008-06-05 | 2016-12-23 | Resmed Ltd | Treatment of respiratory conditions |
EP2294411A4 (en) * | 2008-07-07 | 2017-09-06 | Agamatrix, Inc. | Integrated blood glucose measurement device |
US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
US10089443B2 (en) | 2012-05-15 | 2018-10-02 | Baxter International Inc. | Home medical device systems and methods for therapy prescription and tracking, servicing and inventory |
US8423378B1 (en) | 2008-07-24 | 2013-04-16 | Ideal Life, Inc. | Facilitating health care management of subjects |
EP3881874A1 (en) | 2008-09-15 | 2021-09-22 | DEKA Products Limited Partnership | Systems and methods for fluid delivery |
US20100077458A1 (en) * | 2008-09-25 | 2010-03-25 | Card Access, Inc. | Apparatus, System, and Method for Responsibility-Based Data Management |
US8262616B2 (en) | 2008-10-10 | 2012-09-11 | Deka Products Limited Partnership | Infusion pump assembly |
US8267892B2 (en) | 2008-10-10 | 2012-09-18 | Deka Products Limited Partnership | Multi-language / multi-processor infusion pump assembly |
US8016789B2 (en) | 2008-10-10 | 2011-09-13 | Deka Products Limited Partnership | Pump assembly with a removable cover assembly |
US8223028B2 (en) | 2008-10-10 | 2012-07-17 | Deka Products Limited Partnership | Occlusion detection system and method |
US9180245B2 (en) | 2008-10-10 | 2015-11-10 | Deka Products Limited Partnership | System and method for administering an infusible fluid |
US8066672B2 (en) | 2008-10-10 | 2011-11-29 | Deka Products Limited Partnership | Infusion pump assembly with a backup power supply |
US8708376B2 (en) | 2008-10-10 | 2014-04-29 | Deka Products Limited Partnership | Medium connector |
US8554579B2 (en) | 2008-10-13 | 2013-10-08 | Fht, Inc. | Management, reporting and benchmarking of medication preparation |
US7908154B2 (en) * | 2008-10-27 | 2011-03-15 | MedSleuth, Inc. | System and method for generating a medical history |
US8208973B2 (en) * | 2008-11-05 | 2012-06-26 | Medtronic Minimed, Inc. | System and method for variable beacon timing with wireless devices |
US8849458B2 (en) * | 2008-12-23 | 2014-09-30 | Roche Diagnostics Operations, Inc. | Collection device with selective display of test results, method and computer program product thereof |
US10456036B2 (en) * | 2008-12-23 | 2019-10-29 | Roche Diabetes Care, Inc. | Structured tailoring |
US10437962B2 (en) | 2008-12-23 | 2019-10-08 | Roche Diabetes Care Inc | Status reporting of a structured collection procedure |
US20120011125A1 (en) | 2008-12-23 | 2012-01-12 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
CN102265279B (en) | 2008-12-23 | 2019-08-23 | 霍夫曼-拉罗奇有限公司 | The Structural Testing Method and its equipment that diagnosis or treatment for chronic are supported |
US9117015B2 (en) | 2008-12-23 | 2015-08-25 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US9918635B2 (en) * | 2008-12-23 | 2018-03-20 | Roche Diabetes Care, Inc. | Systems and methods for optimizing insulin dosage |
US20100161346A1 (en) * | 2008-12-24 | 2010-06-24 | Kristen Getschmann | Systems and Methods for Providing Bolus Dosage Recommendations |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US20100249965A1 (en) * | 2009-03-31 | 2010-09-30 | Agamatrix, Inc. | Integrated Blood Glucose Measurement Device |
US8271106B2 (en) | 2009-04-17 | 2012-09-18 | Hospira, Inc. | System and method for configuring a rule set for medical event management and responses |
WO2010127050A1 (en) | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
WO2010138856A1 (en) | 2009-05-29 | 2010-12-02 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US8931481B2 (en) | 2009-06-04 | 2015-01-13 | Redmed Limited | Flow generator chassis assembly with suspension seal |
US20110006880A1 (en) * | 2009-07-09 | 2011-01-13 | Medtronic Minimed, Inc. | Fingerprint-linked control of a portable medical device |
US20110009724A1 (en) * | 2009-07-09 | 2011-01-13 | Medtronic Minimed, Inc. | Providing contextually relevant advertisements and e-commerce features in a personal medical device system |
US8344847B2 (en) * | 2009-07-09 | 2013-01-01 | Medtronic Minimed, Inc. | Coordination of control commands in a medical device system having at least one therapy delivery device and at least one wireless controller device |
CA2768011C (en) | 2009-07-15 | 2018-07-24 | Deka Products Limited Partnership | Apparatus, systems and methods for an infusion pump assembly |
US8993331B2 (en) | 2009-08-31 | 2015-03-31 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US8487758B2 (en) * | 2009-09-02 | 2013-07-16 | Medtronic Minimed, Inc. | Medical device having an intelligent alerting scheme, and related operating methods |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US8386042B2 (en) * | 2009-11-03 | 2013-02-26 | Medtronic Minimed, Inc. | Omnidirectional accelerometer device and medical device incorporating same |
US20110141116A1 (en) * | 2009-12-16 | 2011-06-16 | Baxter International Inc. | Methods and apparatus for displaying flow rate graphs and alarms on a dialysis system |
US8574201B2 (en) | 2009-12-22 | 2013-11-05 | Medtronic Minimed, Inc. | Syringe piston with check valve seal |
US20110152970A1 (en) * | 2009-12-23 | 2011-06-23 | Medtronic Minimed, Inc. | Location-based ranking and switching of wireless channels in a body area network of medical devices |
US8755269B2 (en) * | 2009-12-23 | 2014-06-17 | Medtronic Minimed, Inc. | Ranking and switching of wireless channels in a body area network of medical devices |
JP5844280B2 (en) | 2010-01-22 | 2016-01-13 | デカ・プロダクツ・リミテッド・パートナーシップ | Method and system for shape memory alloy wire control |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
US8562565B2 (en) | 2010-10-15 | 2013-10-22 | Medtronic Minimed, Inc. | Battery shock absorber for a portable medical device |
US8603033B2 (en) | 2010-10-15 | 2013-12-10 | Medtronic Minimed, Inc. | Medical device and related assembly having an offset element for a piezoelectric speaker |
US8603032B2 (en) | 2010-10-15 | 2013-12-10 | Medtronic Minimed, Inc. | Medical device with membrane keypad sealing element, and related manufacturing method |
US8495918B2 (en) | 2010-10-20 | 2013-07-30 | Medtronic Minimed, Inc. | Sensor assembly and medical device incorporating same |
US8474332B2 (en) | 2010-10-20 | 2013-07-02 | Medtronic Minimed, Inc. | Sensor assembly and medical device incorporating same |
US8479595B2 (en) | 2010-10-20 | 2013-07-09 | Medtronic Minimed, Inc. | Sensor assembly and medical device incorporating same |
US8537990B2 (en) | 2010-11-19 | 2013-09-17 | Frederic Rudman | Communications device and method and method of use |
US8690855B2 (en) | 2010-12-22 | 2014-04-08 | Medtronic Minimed, Inc. | Fluid reservoir seating procedure for a fluid infusion device |
US8628510B2 (en) | 2010-12-22 | 2014-01-14 | Medtronic Minimed, Inc. | Monitoring the operating health of a force sensor in a fluid infusion device |
US8469942B2 (en) | 2010-12-22 | 2013-06-25 | Medtronic Minimed, Inc. | Occlusion detection for a fluid infusion device |
US8197444B1 (en) | 2010-12-22 | 2012-06-12 | Medtronic Minimed, Inc. | Monitoring the seating status of a fluid reservoir in a fluid infusion device |
US20120173151A1 (en) | 2010-12-29 | 2012-07-05 | Roche Diagnostics Operations, Inc. | Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels |
US8532775B2 (en) | 2011-02-18 | 2013-09-10 | Medtronic, Inc. | Modular medical device programmer |
WO2012112179A1 (en) | 2011-02-18 | 2012-08-23 | Medtronic, Inc. | Medical device programmer with adjustable kickstand |
US9393399B2 (en) | 2011-02-22 | 2016-07-19 | Medtronic Minimed, Inc. | Sealing assembly for a fluid reservoir of a fluid infusion device |
US9283318B2 (en) | 2011-02-22 | 2016-03-15 | Medtronic Minimed, Inc. | Flanged sealing element and needle guide pin assembly for a fluid infusion device having a needled fluid reservoir |
US9463309B2 (en) | 2011-02-22 | 2016-10-11 | Medtronic Minimed, Inc. | Sealing assembly and structure for a fluid infusion device having a needled fluid reservoir |
US8870829B2 (en) | 2011-02-22 | 2014-10-28 | Medtronic Minimed, Inc. | Fluid infusion device and related sealing assembly for a needleless fluid reservoir |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US8614596B2 (en) | 2011-02-28 | 2013-12-24 | Medtronic Minimed, Inc. | Systems and methods for initializing a voltage bus and medical devices incorporating same |
US9101305B2 (en) | 2011-03-09 | 2015-08-11 | Medtronic Minimed, Inc. | Glucose sensor product and related manufacturing and packaging methods |
US9018893B2 (en) | 2011-03-18 | 2015-04-28 | Medtronic Minimed, Inc. | Power control techniques for an electronic device |
US8564447B2 (en) | 2011-03-18 | 2013-10-22 | Medtronic Minimed, Inc. | Battery life indication techniques for an electronic device |
USD694909S1 (en) | 2011-10-12 | 2013-12-03 | HealthSpot Inc. | Medical kiosk |
US8755938B2 (en) | 2011-05-13 | 2014-06-17 | Roche Diagnostics Operations, Inc. | Systems and methods for handling unacceptable values in structured collection protocols |
US8766803B2 (en) | 2011-05-13 | 2014-07-01 | Roche Diagnostics Operations, Inc. | Dynamic data collection |
US9240002B2 (en) | 2011-08-19 | 2016-01-19 | Hospira, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
JP6033874B2 (en) | 2011-10-21 | 2016-11-30 | ホスピーラ インコーポレイテッド | Medical device update system |
AU2012335830B2 (en) | 2011-11-07 | 2017-05-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US10022498B2 (en) | 2011-12-16 | 2018-07-17 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US9610401B2 (en) | 2012-01-13 | 2017-04-04 | Medtronic Minimed, Inc. | Infusion set component with modular fluid channel element |
WO2013134519A2 (en) | 2012-03-07 | 2013-09-12 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US8603026B2 (en) | 2012-03-20 | 2013-12-10 | Medtronic Minimed, Inc. | Dynamic pulse-width modulation motor control and medical device incorporating same |
US8523803B1 (en) | 2012-03-20 | 2013-09-03 | Medtronic Minimed, Inc. | Motor health monitoring and medical device incorporating same |
US8603027B2 (en) | 2012-03-20 | 2013-12-10 | Medtronic Minimed, Inc. | Occlusion detection using pulse-width modulation and medical device incorporating same |
AU2013239778B2 (en) | 2012-03-30 | 2017-09-28 | Icu Medical, Inc. | Air detection system and method for detecting air in a pump of an infusion system |
US10391242B2 (en) | 2012-06-07 | 2019-08-27 | Medtronic Minimed, Inc. | Diabetes therapy management system for recommending bolus calculator adjustments |
JP5726996B2 (en) * | 2012-06-21 | 2015-06-03 | シャープ株式会社 | Communication terminal and monitoring information display method |
US9333292B2 (en) | 2012-06-26 | 2016-05-10 | Medtronic Minimed, Inc. | Mechanically actuated fluid infusion device |
CA3089257C (en) | 2012-07-31 | 2023-07-25 | Icu Medical, Inc. | Patient care system for critical medications |
US8808269B2 (en) | 2012-08-21 | 2014-08-19 | Medtronic Minimed, Inc. | Reservoir plunger position monitoring and medical device incorporating same |
US9878096B2 (en) | 2012-08-30 | 2018-01-30 | Medtronic Minimed, Inc. | Generation of target glucose values for a closed-loop operating mode of an insulin infusion system |
US9662445B2 (en) | 2012-08-30 | 2017-05-30 | Medtronic Minimed, Inc. | Regulating entry into a closed-loop operating mode of an insulin infusion system |
US9623179B2 (en) | 2012-08-30 | 2017-04-18 | Medtronic Minimed, Inc. | Safeguarding techniques for a closed-loop insulin infusion system |
US10496797B2 (en) | 2012-08-30 | 2019-12-03 | Medtronic Minimed, Inc. | Blood glucose validation for a closed-loop operating mode of an insulin infusion system |
US20140066884A1 (en) | 2012-08-30 | 2014-03-06 | Medtronic Minimed, Inc. | Sensor model supervisor for a closed-loop insulin infusion system |
US10130767B2 (en) | 2012-08-30 | 2018-11-20 | Medtronic Minimed, Inc. | Sensor model supervisor for a closed-loop insulin infusion system |
US9849239B2 (en) | 2012-08-30 | 2017-12-26 | Medtronic Minimed, Inc. | Generation and application of an insulin limit for a closed-loop operating mode of an insulin infusion system |
SG11201501427PA (en) | 2012-08-31 | 2015-03-30 | Baxter Corp Englewood | Medication requisition fulfillment system and method |
US9256988B2 (en) | 2012-09-11 | 2016-02-09 | Black & Decker Inc. | System and method for identifying a power tool |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
CA2889210C (en) | 2012-10-26 | 2020-12-15 | Baxter Corporation Englewood | Improved image acquisition for medical dose preparation system |
NZ707430A (en) | 2012-10-26 | 2016-04-29 | Baxter Corp Englewood | Improved work station for medical dose preparation system |
US8870818B2 (en) | 2012-11-15 | 2014-10-28 | Medtronic Minimed, Inc. | Systems and methods for alignment and detection of a consumable component |
US9251713B1 (en) * | 2012-11-20 | 2016-02-02 | Anthony J. Giovanniello | System and process for assessing a user and for assisting a user in rehabilitation |
US9395234B2 (en) | 2012-12-05 | 2016-07-19 | Cardiocom, Llc | Stabilizing base for scale |
US9801541B2 (en) | 2012-12-31 | 2017-10-31 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US9730621B2 (en) | 2012-12-31 | 2017-08-15 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US9107994B2 (en) | 2013-01-18 | 2015-08-18 | Medtronic Minimed, Inc. | Systems for fluid reservoir retention |
US9522223B2 (en) | 2013-01-18 | 2016-12-20 | Medtronic Minimed, Inc. | Systems for fluid reservoir retention |
US9033924B2 (en) | 2013-01-18 | 2015-05-19 | Medtronic Minimed, Inc. | Systems for fluid reservoir retention |
EP2948204B1 (en) | 2013-01-28 | 2021-08-25 | Smiths Medical ASD, Inc. | Medication safety devices and methods |
US9308321B2 (en) | 2013-02-18 | 2016-04-12 | Medtronic Minimed, Inc. | Infusion device having gear assembly initialization |
WO2014138446A1 (en) | 2013-03-06 | 2014-09-12 | Hospira,Inc. | Medical device communication method |
US9903879B2 (en) * | 2013-03-14 | 2018-02-27 | Lifescan Scotland Limited | Method to allow for linking temporal record with physiological measurement in buttonless physiological meters |
US9929985B1 (en) * | 2013-03-15 | 2018-03-27 | Quest Diagnostics Investments Incorporated | Systems and methods for electronically distributing information |
US8920381B2 (en) | 2013-04-12 | 2014-12-30 | Medtronic Minimed, Inc. | Infusion set with improved bore configuration |
AU2014268355B2 (en) | 2013-05-24 | 2018-06-14 | Icu Medical, Inc. | Multi-sensor infusion system for detecting air or an occlusion in the infusion system |
CA2913918C (en) | 2013-05-29 | 2022-02-15 | Hospira, Inc. | Infusion system and method of use which prevents over-saturation of an analog-to-digital converter |
CA2913915C (en) | 2013-05-29 | 2022-03-29 | Hospira, Inc. | Infusion system which utilizes one or more sensors and additional information to make an air determination regarding the infusion system |
US9955869B2 (en) * | 2013-06-04 | 2018-05-01 | Purdue Pharma L.P. | System and method for supporting health management services |
US10545132B2 (en) | 2013-06-25 | 2020-01-28 | Lifescan Ip Holdings, Llc | Physiological monitoring system communicating with at least a social network |
EP4309699A3 (en) | 2013-07-03 | 2024-04-24 | DEKA Products Limited Partnership | Apparatus and system for fluid delivery |
US9433731B2 (en) | 2013-07-19 | 2016-09-06 | Medtronic Minimed, Inc. | Detecting unintentional motor motion and infusion device incorporating same |
US9402949B2 (en) | 2013-08-13 | 2016-08-02 | Medtronic Minimed, Inc. | Detecting conditions associated with medical device operations using matched filters |
US9889257B2 (en) | 2013-08-21 | 2018-02-13 | Medtronic Minimed, Inc. | Systems and methods for updating medical devices |
US9880528B2 (en) | 2013-08-21 | 2018-01-30 | Medtronic Minimed, Inc. | Medical devices and related updating methods and systems |
US9259528B2 (en) | 2013-08-22 | 2016-02-16 | Medtronic Minimed, Inc. | Fluid infusion device with safety coupling |
US20150066531A1 (en) | 2013-08-30 | 2015-03-05 | James D. Jacobson | System and method of monitoring and managing a remote infusion regimen |
US9662436B2 (en) | 2013-09-20 | 2017-05-30 | Icu Medical, Inc. | Fail-safe drug infusion therapy system |
US10311972B2 (en) | 2013-11-11 | 2019-06-04 | Icu Medical, Inc. | Medical device system performance index |
AU2014353130B9 (en) | 2013-11-19 | 2019-09-05 | Icu Medical, Inc. | Infusion pump automation system and method |
US9750877B2 (en) | 2013-12-11 | 2017-09-05 | Medtronic Minimed, Inc. | Predicted time to assess and/or control a glycemic state |
US9750878B2 (en) | 2013-12-11 | 2017-09-05 | Medtronic Minimed, Inc. | Closed-loop control of glucose according to a predicted blood glucose trajectory |
US10105488B2 (en) | 2013-12-12 | 2018-10-23 | Medtronic Minimed, Inc. | Predictive infusion device operations and related methods and systems |
US9849240B2 (en) | 2013-12-12 | 2017-12-26 | Medtronic Minimed, Inc. | Data modification for predictive operations and devices incorporating same |
US9694132B2 (en) | 2013-12-19 | 2017-07-04 | Medtronic Minimed, Inc. | Insertion device for insertion set |
US9861748B2 (en) | 2014-02-06 | 2018-01-09 | Medtronic Minimed, Inc. | User-configurable closed-loop notifications and infusion systems incorporating same |
US9399096B2 (en) | 2014-02-06 | 2016-07-26 | Medtronic Minimed, Inc. | Automatic closed-loop control adjustments and infusion systems incorporating same |
ES2776363T3 (en) | 2014-02-28 | 2020-07-30 | Icu Medical Inc | Infusion set and method using dual wavelength in-line optical air detection |
US9987422B2 (en) | 2014-03-24 | 2018-06-05 | Medtronic Minimed, Inc. | Fluid infusion patch pump device with automatic startup feature |
US10001450B2 (en) | 2014-04-18 | 2018-06-19 | Medtronic Minimed, Inc. | Nonlinear mapping technique for a physiological characteristic sensor |
US10232113B2 (en) | 2014-04-24 | 2019-03-19 | Medtronic Minimed, Inc. | Infusion devices and related methods and systems for regulating insulin on board |
WO2015168427A1 (en) | 2014-04-30 | 2015-11-05 | Hospira, Inc. | Patient care system with conditional alarm forwarding |
US9681828B2 (en) | 2014-05-01 | 2017-06-20 | Medtronic Minimed, Inc. | Physiological characteristic sensors and methods for forming such sensors |
US10275572B2 (en) | 2014-05-01 | 2019-04-30 | Medtronic Minimed, Inc. | Detecting blockage of a reservoir cavity during a seating operation of a fluid infusion device |
US10007765B2 (en) | 2014-05-19 | 2018-06-26 | Medtronic Minimed, Inc. | Adaptive signal processing for infusion devices and related methods and systems |
US10274349B2 (en) | 2014-05-19 | 2019-04-30 | Medtronic Minimed, Inc. | Calibration factor adjustments for infusion devices and related methods and systems |
US10152049B2 (en) | 2014-05-19 | 2018-12-11 | Medtronic Minimed, Inc. | Glucose sensor health monitoring and related methods and systems |
AU2015266706B2 (en) | 2014-05-29 | 2020-01-30 | Icu Medical, Inc. | Infusion system and pump with configurable closed loop delivery rate catch-up |
US9724470B2 (en) | 2014-06-16 | 2017-08-08 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
WO2016003902A1 (en) | 2014-06-30 | 2016-01-07 | Baxter Corporation Englewood | Managed medical information exchange |
US9687419B2 (en) | 2014-09-12 | 2017-06-27 | Becton, Dickinson And Company | Assisted medication filling and management |
US9539383B2 (en) | 2014-09-15 | 2017-01-10 | Hospira, Inc. | System and method that matches delayed infusion auto-programs with manually entered infusion programs and analyzes differences therein |
US9839753B2 (en) | 2014-09-26 | 2017-12-12 | Medtronic Minimed, Inc. | Systems for managing reservoir chamber pressure |
US9833563B2 (en) | 2014-09-26 | 2017-12-05 | Medtronic Minimed, Inc. | Systems for managing reservoir chamber pressure |
US11575673B2 (en) | 2014-09-30 | 2023-02-07 | Baxter Corporation Englewood | Central user management in a distributed healthcare information management system |
US11107574B2 (en) | 2014-09-30 | 2021-08-31 | Baxter Corporation Englewood | Management of medication preparation with formulary management |
US10279126B2 (en) | 2014-10-07 | 2019-05-07 | Medtronic Minimed, Inc. | Fluid conduit assembly with gas trapping filter in the fluid flow path |
US9833564B2 (en) | 2014-11-25 | 2017-12-05 | Medtronic Minimed, Inc. | Fluid conduit assembly with air venting features |
US10195341B2 (en) | 2014-11-26 | 2019-02-05 | Medtronic Minimed, Inc. | Systems and methods for fluid infusion device with automatic reservoir fill |
US9987420B2 (en) | 2014-11-26 | 2018-06-05 | Medtronic Minimed, Inc. | Systems and methods for fluid infusion device with automatic reservoir fill |
US9636453B2 (en) | 2014-12-04 | 2017-05-02 | Medtronic Minimed, Inc. | Advance diagnosis of infusion device operating mode viability |
US9943645B2 (en) | 2014-12-04 | 2018-04-17 | Medtronic Minimed, Inc. | Methods for operating mode transitions and related infusion devices and systems |
AU2015358483A1 (en) | 2014-12-05 | 2017-06-15 | Baxter Corporation Englewood | Dose preparation data analytics |
US9937292B2 (en) | 2014-12-09 | 2018-04-10 | Medtronic Minimed, Inc. | Systems for filling a fluid infusion device reservoir |
US11344668B2 (en) | 2014-12-19 | 2022-05-31 | Icu Medical, Inc. | Infusion system with concurrent TPN/insulin infusion |
US10307535B2 (en) | 2014-12-19 | 2019-06-04 | Medtronic Minimed, Inc. | Infusion devices and related methods and systems for preemptive alerting |
US10265031B2 (en) | 2014-12-19 | 2019-04-23 | Medtronic Minimed, Inc. | Infusion devices and related methods and systems for automatic alert clearing |
US10850024B2 (en) | 2015-03-02 | 2020-12-01 | Icu Medical, Inc. | Infusion system, device, and method having advanced infusion features |
CA2978455A1 (en) | 2015-03-03 | 2016-09-09 | Baxter Corporation Englewood | Pharmacy workflow management with integrated alerts |
US10307528B2 (en) | 2015-03-09 | 2019-06-04 | Medtronic Minimed, Inc. | Extensible infusion devices and related methods |
US10449298B2 (en) | 2015-03-26 | 2019-10-22 | Medtronic Minimed, Inc. | Fluid injection devices and related methods |
CN107548548B (en) | 2015-05-12 | 2021-09-14 | 德克斯康公司 | Distributed system architecture for continuous glucose monitoring |
US9999721B2 (en) | 2015-05-26 | 2018-06-19 | Medtronic Minimed, Inc. | Error handling in infusion devices with distributed motor control and related operating methods |
WO2016189417A1 (en) | 2015-05-26 | 2016-12-01 | Hospira, Inc. | Infusion pump system and method with multiple drug library editor source capability |
US10137243B2 (en) | 2015-05-26 | 2018-11-27 | Medtronic Minimed, Inc. | Infusion devices with distributed motor control and related operating methods |
US10575767B2 (en) | 2015-05-29 | 2020-03-03 | Medtronic Minimed, Inc. | Method for monitoring an analyte, analyte sensor and analyte monitoring apparatus |
US10010668B2 (en) | 2015-06-22 | 2018-07-03 | Medtronic Minimed, Inc. | Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and a force sensor |
US9987425B2 (en) | 2015-06-22 | 2018-06-05 | Medtronic Minimed, Inc. | Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and sensor contact elements |
US9879668B2 (en) | 2015-06-22 | 2018-01-30 | Medtronic Minimed, Inc. | Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and an optical sensor |
US9993594B2 (en) | 2015-06-22 | 2018-06-12 | Medtronic Minimed, Inc. | Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and rotor position sensors |
US9878095B2 (en) | 2015-06-22 | 2018-01-30 | Medtronic Minimed, Inc. | Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and multiple sensor contact elements |
CA2985719C (en) | 2015-06-25 | 2024-03-26 | Gambro Lundia Ab | Medical device system and method having a distributed database |
US20170053552A1 (en) | 2015-08-21 | 2017-02-23 | Medtronic Minimed, Inc. | Management and prioritization of the delivery of glycemic insight messages |
US10478557B2 (en) | 2015-08-21 | 2019-11-19 | Medtronic Minimed, Inc. | Personalized parameter modeling methods and related devices and systems |
US10293108B2 (en) | 2015-08-21 | 2019-05-21 | Medtronic Minimed, Inc. | Infusion devices and related patient ratio adjustment methods |
US10463297B2 (en) | 2015-08-21 | 2019-11-05 | Medtronic Minimed, Inc. | Personalized event detection methods and related devices and systems |
US10201657B2 (en) | 2015-08-21 | 2019-02-12 | Medtronic Minimed, Inc. | Methods for providing sensor site rotation feedback and related infusion devices and systems |
DE102015217826A1 (en) * | 2015-09-17 | 2017-03-23 | Robert Bosch Gmbh | Communication device for an electric machine tool, power tool system and method |
US10117992B2 (en) | 2015-09-29 | 2018-11-06 | Medtronic Minimed, Inc. | Infusion devices and related rescue detection methods |
US11501867B2 (en) | 2015-10-19 | 2022-11-15 | Medtronic Minimed, Inc. | Medical devices and related event pattern presentation methods |
US11666702B2 (en) | 2015-10-19 | 2023-06-06 | Medtronic Minimed, Inc. | Medical devices and related event pattern treatment recommendation methods |
US10146911B2 (en) | 2015-10-23 | 2018-12-04 | Medtronic Minimed, Inc. | Medical devices and related methods and systems for data transfer |
US10037722B2 (en) | 2015-11-03 | 2018-07-31 | Medtronic Minimed, Inc. | Detecting breakage in a display element |
US10449306B2 (en) | 2015-11-25 | 2019-10-22 | Medtronics Minimed, Inc. | Systems for fluid delivery with wicking membrane |
US11399721B2 (en) | 2015-12-28 | 2022-08-02 | Dexcom, Inc. | Systems and methods for remote and host monitoring communications |
SG11201808475XA (en) | 2016-04-15 | 2018-10-30 | Baxalta Inc | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
US10589038B2 (en) | 2016-04-27 | 2020-03-17 | Medtronic Minimed, Inc. | Set connector systems for venting a fluid reservoir |
AU2017264784B2 (en) | 2016-05-13 | 2022-04-21 | Icu Medical, Inc. | Infusion pump system and method with common line auto flush |
EP3468635A4 (en) | 2016-06-10 | 2019-11-20 | ICU Medical, Inc. | Acoustic flow sensor for continuous medication flow measurements and feedback control of infusion |
EP3484541A4 (en) | 2016-07-14 | 2020-03-25 | ICU Medical, Inc. | Multi-communication path selection and security system for a medical device |
US11097051B2 (en) | 2016-11-04 | 2021-08-24 | Medtronic Minimed, Inc. | Methods and apparatus for detecting and reacting to insufficient hypoglycemia response |
US10238030B2 (en) | 2016-12-06 | 2019-03-26 | Medtronic Minimed, Inc. | Wireless medical device with a complementary split ring resonator arrangement for suppression of electromagnetic interference |
AU2017381172A1 (en) | 2016-12-21 | 2019-06-13 | Gambro Lundia Ab | Medical device system including information technology infrastructure having secure cluster domain supporting external domain |
US10272201B2 (en) | 2016-12-22 | 2019-04-30 | Medtronic Minimed, Inc. | Insertion site monitoring methods and related infusion devices and systems |
US9974111B1 (en) | 2017-01-06 | 2018-05-15 | Sorenson Ip Holdings, Llc | Establishment of communication between devices |
US9773501B1 (en) | 2017-01-06 | 2017-09-26 | Sorenson Ip Holdings, Llc | Transcription of communication sessions |
US9787842B1 (en) | 2017-01-06 | 2017-10-10 | Sorenson Ip Holdings, Llc | Establishment of communication between devices |
US9787941B1 (en) | 2017-01-06 | 2017-10-10 | Sorenson Ip Holdings, Llc | Device to device communication |
US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
US10532165B2 (en) | 2017-01-30 | 2020-01-14 | Medtronic Minimed, Inc. | Fluid reservoir and systems for filling a fluid reservoir of a fluid infusion device |
US10500135B2 (en) | 2017-01-30 | 2019-12-10 | Medtronic Minimed, Inc. | Fluid reservoir and systems for filling a fluid reservoir of a fluid infusion device |
US10552580B2 (en) | 2017-02-07 | 2020-02-04 | Medtronic Minimed, Inc. | Infusion system consumables and related calibration methods |
US10363365B2 (en) | 2017-02-07 | 2019-07-30 | Medtronic Minimed, Inc. | Infusion devices and related consumable calibration methods |
US11207463B2 (en) | 2017-02-21 | 2021-12-28 | Medtronic Minimed, Inc. | Apparatuses, systems, and methods for identifying an infusate in a reservoir of an infusion device |
US10646649B2 (en) | 2017-02-21 | 2020-05-12 | Medtronic Minimed, Inc. | Infusion devices and fluid identification apparatuses and methods |
US10089055B1 (en) | 2017-12-27 | 2018-10-02 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
EP3784312A1 (en) | 2018-04-24 | 2021-03-03 | DEKA Products Limited Partnership | Apparatus and system for fluid delivery |
NZ793485A (en) | 2018-07-17 | 2023-06-30 | Icu Medical Inc | Systems and methods for facilitating clinical messaging in a network environment |
CA3106516C (en) | 2018-07-17 | 2023-07-25 | Icu Medical, Inc. | Updating infusion pump drug libraries and operational software in a networked environment |
US11139058B2 (en) | 2018-07-17 | 2021-10-05 | Icu Medical, Inc. | Reducing file transfer between cloud environment and infusion pumps |
US10964428B2 (en) | 2018-07-17 | 2021-03-30 | Icu Medical, Inc. | Merging messages into cache and generating user interface using the cache |
US10692595B2 (en) | 2018-07-26 | 2020-06-23 | Icu Medical, Inc. | Drug library dynamic version management |
WO2020023231A1 (en) | 2018-07-26 | 2020-01-30 | Icu Medical, Inc. | Drug library management system |
US10764640B2 (en) * | 2018-11-23 | 2020-09-01 | Sony Corporation | Receiver device including native broadcaster application |
CN110866832A (en) * | 2019-09-30 | 2020-03-06 | 北京健康之家科技有限公司 | Risk control method, system, storage medium and computing device |
US11278671B2 (en) | 2019-12-04 | 2022-03-22 | Icu Medical, Inc. | Infusion pump with safety sequence keypad |
AU2021311443A1 (en) | 2020-07-21 | 2023-03-09 | Icu Medical, Inc. | Fluid transfer devices and methods of use |
US11135360B1 (en) | 2020-12-07 | 2021-10-05 | Icu Medical, Inc. | Concurrent infusion with common line auto flush |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5558638A (en) * | 1993-04-30 | 1996-09-24 | Healthdyne, Inc. | Patient monitor and support system |
US5660176A (en) * | 1993-12-29 | 1997-08-26 | First Opinion Corporation | Computerized medical diagnostic and treatment advice system |
US5827179A (en) * | 1997-02-28 | 1998-10-27 | Qrs Diagnostic, Llc | Personal computer card for collection for real-time biological data |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933876A (en) * | 1988-12-28 | 1990-06-12 | Vital Lasertype, Inc. | System of operating an automatic plotter |
US5642731A (en) * | 1990-01-17 | 1997-07-01 | Informedix, Inc. | Method of and apparatus for monitoring the management of disease |
US5262943A (en) * | 1991-10-15 | 1993-11-16 | National Computer Systems, Inc. | System and process for information management and reporting |
US5441047A (en) * | 1992-03-25 | 1995-08-15 | David; Daniel | Ambulatory patient health monitoring techniques utilizing interactive visual communication |
-
1997
- 1997-04-30 US US08/847,009 patent/US5897493A/en not_active Expired - Lifetime
-
2011
- 2011-11-23 US US13/303,622 patent/US20120130647A1/en not_active Abandoned
-
2012
- 2012-02-29 US US13/408,334 patent/US20120203466A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5558638A (en) * | 1993-04-30 | 1996-09-24 | Healthdyne, Inc. | Patient monitor and support system |
US5660176A (en) * | 1993-12-29 | 1997-08-26 | First Opinion Corporation | Computerized medical diagnostic and treatment advice system |
US5827179A (en) * | 1997-02-28 | 1998-10-27 | Qrs Diagnostic, Llc | Personal computer card for collection for real-time biological data |
Non-Patent Citations (2)
Title |
---|
Altman, R. B. Informatics in the care of patients: ten notable challenges. The Western Journal of Medicine 166, 118-122 (1997). * |
Yang, Q. & Khoury, M. J. Evolving Methods in Genetic Epidemiology. III. Gene-Environment Interaction in Epidemiologic Research. Epidemiologic Reviews 19, 33-43 (1997). * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8996392B2 (en) | 2011-03-31 | 2015-03-31 | Healthspot, Inc. | Medical kiosk and method of use |
US9043217B2 (en) | 2011-03-31 | 2015-05-26 | HealthSpot Inc. | Medical kiosk and method of use |
US10074148B2 (en) | 2011-03-31 | 2018-09-11 | Rite Aid Hdqtrs. Corp. | Medical kiosk and method of use |
US10223681B2 (en) | 2012-08-15 | 2019-03-05 | Rite Aid Hdqtrs. Corp. | Veterinary kiosk with integrated veterinary medical devices |
Also Published As
Publication number | Publication date |
---|---|
US5897493A (en) | 1999-04-27 |
US20120130647A1 (en) | 2012-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120203466A1 (en) | System and method for identifying disease-influencing genes | |
US20060200319A1 (en) | System and method for identifying disease-influencing genes | |
US8107693B2 (en) | Artificial intelligence system for genetic analysis | |
EP1222602B1 (en) | Artificial intelligence system for genetic analysis | |
US8571810B2 (en) | Information processing system using nucleotide sequence-related information | |
CN109686439B (en) | Data analysis method, system and storage medium for genetic disease gene detection | |
US20040236723A1 (en) | Method and system for data evaluation, corresponding computer program product, and corresponding computer-readable storage medium | |
WO2003009210A1 (en) | Methods of providing customized gene annotation reports | |
EP1410299A2 (en) | System and method for genomic and proteomic human disease assessment via expression profile comparison | |
JPWO2002025519A1 (en) | Genetic medical information providing method, medical information providing terminal, and medical information receiving terminal | |
MXPA04002684A (en) | Systems, methods and kits for remote genetic analysis and consultation. | |
JP2004348749A (en) | Medical information system, system and method for providing medical information, and gene analysis system | |
EP1598765A1 (en) | Information processing system using base sequence relevant information | |
EP1111525A2 (en) | A method of guaranteeing the quality of a product with biotechnology and a method of delivering gene information | |
EP1569154A1 (en) | Data processing system using base sequence-relating data | |
WO2002037940A2 (en) | System and method for biological sample analysis and adaptive diagnostic device creation | |
Hood | A big circuit model. | |
Potera | Fingerprinting cancer development. | |
Dahl | The EGP at five years. | |
WO2004111908A1 (en) | Information processing system using base sequence related information |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |